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 ABSTRACT 
STUDIES ON ESTRADIOL DEPENDENT TRANSCRIPTIONAL 
REGULATION OF HUMAN SODIUM IODIDE SYMPORTER GENE IN 
MAMMARY GLANDS 
Neriman Tuba Gülbağcı 
M.S. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. H. Uygar Tazebay 
August 2002, 64 pages 
Sodium Iodide Symporter (NIS) is a transmembrane protein, which is 
expressed in thyroid, mammary gland (mg), stomach, and salivary gland. NIS’s 
transcriptional regulation in terms of cis-and trans-acting elements in thyroid gland is 
widely studied. However, despite identification of NIS and studies on its hormonal 
regulation in mammary gland, cis-and trans-acting elements controlling the mgNIS 
gene in this tissue are not identified yet. From in vivo experiments, it was learned that 
estrogen has an up regulatory effect on mgNIS transcriptional regulation. In this 
study, it was shown that in vitro, estrogen (even in pharmacological concentrations) 
was not able to induce mgNIS in estrogen receptor positive (ER(+)) MCF-7 breast 
carcinoma cells, and it had no additive effect on retinoic acid (RA) in NIS up 
regulation when it was administered in physiological concentrations. In ER (-) 
MDA-MB-231 breast cancarcinoma cells, ERα might be insufficient to induce 
mgNIS transcription inspite of the fact that ERα was able to transactivate ERE 
elements. Interestingly, our study indicates that  tamoxifen antagonist of ER, together 
with estrogen induces mgNIS transcription in MCF-7 cell lines in the absence of RA. 
This study clearly shows the presence of a yet unidentified link between mgNIS 
regulation and estrogen responsive mechanisms. Bearing in mind that tamoxifen is a 
powerful substance in treatment of  ER(+) breast cancers, and that radioactive iodide 
is used in thyroid cancer diagnosis and treatment. This weak induction of mgNIS 
expression in response to tamoxifen may also have interesting novel applications in 
fight against breast cancer. 
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ÖZET 
Meme Dokusunda Sodyum İyot Taşıyıcı Proteinin  
Estradiyol ile Regülasyonu 
 
Neriman Tuba Gülbağcı 
M.S. Moleküler Biyoloji ve Genetik 
Danışman: Assist. Prof. H. Uygar Tazebay 
Ağustos 2002, 64 sayfa 
Sodyum İyot Taşıyıcısı (NIS) tiroid bezi, meme dokusu, miğde ve tükrük bezlerinde 
sentezlenen bir hücre zarı proteinidir. NIS proteininin tiroid bezindeki 
transkripsiyonel kontrolünde rol alan cis- ve trans-etkin genetik elemanlar daha önce 
belirlenmiştir. Nevar ki meme dokusunda NIS’in transkripsiyonunun hangi 
hormonlar tarafından düzenlendiği belirlenmiş ancak cis- ve trans-etkin elemanlar 
henüz belirlenmemiştir. Farelerle yapılan in vivo deneylerde elde edilen sonuçlarda 
östrojenin memede NIS transkripsiyonel düzenlenmesinde indükleyici bir etkisi 
olduğu gösterilmişti. Bu çalışmada, (ER(+) östrojen reseptörü içeren MCF-7 meme 
kanser hücrelerinde yapılan araştırmalar, bu hücre hattında NIS transkripsiyonunu 
artırabilmek için retinoik asitin gerekli olduğunu ancak estradiolun bu artışa etkisi 
olmadığını göstermiştir. ER(-) MDA-MB-231 meme kanser hücrelerinde ERα nın 
varlığı ERE elemanları indüklemesine rağmen mgNIS transkripsiyonunu 
indükleyebilmek için yetersiz kalmıştır. İlginç bir sonuç olarak, çalışmamız ER 
antagonisti olan tamoksifenin MCF-7 hücrelerinde RA yokluğuna rağmen NIS 
transkripsiyonunu indüklediğini göstermiştir. Bu sonuç memede NIS regulasyonu ve 
östrojene dayalı kontrol mekanizmaları arasında bir ilişki olduğuna işaret etmektedir. 
ER(+) meme kanseri tedavisinde kullanılan etkin bir ilaç olan tamoksifenin bir de 
NIS genini memede artırması, tamoksifen tedavisine tabi tutulan tümörlerin 
radyoaktif iyot izotopları kullanılarak da gözlemlenmesini ve kontrol altında 
tutulmasını sağlayabilmesi açısından oldukça ilginç ve meme kanserinde tedaviye 
yönelik uygulamaları olabilecek bir sonuçtur. 
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1.1. Iodide Transport 
The metabolism of iodide (I-) is mostly associated with the thyroid gland, because I- 
is an essential constituent of the thyroid hormones triiodothyronine (T3), and 
thyroxine (T4). Under physiological conditions, most of the ingested dietary I- is 
accumulated in the thyroid by means of a highly specific active I- transport 
mechanism (De la Vieja et al., 2000). This transport mechanism is an important 
cellular adaptation to accumulate iodine, an environmentally scarce element. Iodine 
constitutes just 4-10% of the litosphere; its main sources on the planet are Chilean 
nitrate deposits, California oil well brines, and sea water (Carrasco et al. 1993). 
I- transport into the thyrocytes is the first and rate-limiting step in the 
biosynthesis of the thyroid hormones. These hormones are of major significance for 
the intermediary metabolism of virtually all tissues. Moreover, they play an essential 
role in the growth and maturation of the skeletal muscles and nervous system and 
lungs of the fetus and the newborn (Stubbe et al. 1986).  
Besides the thyroid, iodide is known to accumulate in other organs or tissues 
such as the salivary glands, gastric mucosa, lactating mammary gland, choroid 
plexus, and the ciliary body of the eye (Carrasco et al. 1993). Striking similarities 
between the iodide transporting systems such as thiocyanate and perchlorate 
inhibition, Na+ dependency, identical specificity, and similar kinetic parameters for 
iodide transport have been found in all these tissues. This, even before the 
identification of the iodide transporters in these tissues, led researchers to think that 
these transport systems may be very similar or identical (Vulsma et al., 1991). 
However, there are also important differences between these transport systems: 1) 
non-thyroid I- transporting tissues do not have the ability to organify the accumulated 
I-; 2) Thyroid Stimulating Hormone (TSH) exerts no regulatory role on non-thyroid 
tissue iodide accumulation; 3) unlike thyroid, salivary glands and gastric mucosa 
concentrate thiocyanate (Carrasco et al. 1993). 
Functional significance of iodide transport in non-thyroidal tissues was 
studied by various groups. An active I- translocating mechanism has been 
demonstrated in the choroid plexus in vitro, and has been suggested to be 
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physiologically responsible for the extraction of I- out of the cerebrospinal fluid 
(Carrasco et al. 1993). Similarly, the ciliary body of the eye has been shown to 
translocate I- out of the aquous humor in rabbits (Carrasco et al. 1993). The existence 
of an active I- transport system in the ducts of the salivary glands results in a higher 
concentration of I- in saliva as compared to plasma. Similarly, I- is actively 
transported from plasma to gastric secretions by an I- translocating system (Spitzweg 
et al., 1998). Also, lactating mammary gland is capable of taking up iodide and 
concentrating it in milk (Carrasco et al. 1993; Tazebay et al., 2000). This supplies I- 
to the newborn. Remarkably, non-lactating breast tissue does not accumulate I- 
(Tazebay et al., 2000). During both the intrauterine and extrauterine stages of 
development, I- is used for the biosynthesis of thyroid hormones by the infant’s 
thyroid gland, which becomes active by the 12th week of gestation in humans (Fisher 
et al. 1990) 
The gene encoding for the Na+/I- Symporter (NIS) of the rat thyroid was 
cloned by Dai et al. in 1996. Subsequently, Smanik et al. has cloned the human 
counterpart of this gene by a PCR based method, and identified it’s chromosomal 
location. The gene is located on chromosome 19p12 and composed of 15 exons and 
14 introns (Smanik et al., 1996). Lack of functional mutations in this gene is found in 
37 numbers of families (Matsuda et al. 1997). This type of mutations in this gene 
lead to a genetic disorder known as iodide transport disorder (ITD), which is inability 
of the thyroid to maintain an iodide concentration difference between the plasma and 
the thyroid.  
In 1998, Spitzweg et al. made RT-PCR, and Northern blot analysis with 
several extrathyroidal human tissues with human thyroid NIS cDNA. They detected 
NIS mRNA by Northern blot, primarily in salivary glands, pituitary gland, pancreas, 
testis, mammary gland, gastric mucosa, prostate, and ovary. Spitzweg et al. also 
sequenced hNIS cDNA which was cloned from gastric mucosa, parotid gland, and 
mammary gland, and were able to show that all hNIS cDNA from different 
extrathyroidal tissues were identical to hNIS cDNA identified in thyroid (Spitzweg et 
al., 1998). 
The protein encoded by the rat NIS gene is analysed both by computer and by 
biochemical and immunological experimental methods (Levy et al. 1998). I- 
transport to thyroid cells is catalyzed by the sodium/iodide (Na+/I-) symporter (NIS), 
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a 618 amino acid 13 putative transmembrane glycoprotein located in the basolateral 
plasma membrane of the thyroid follicular cells (Levy et al. 1998).  
NIS activity is Na-dependent and electrogenic, and the stoichiometry of co-
transport is 2Na+:1I-. From the kinetics of transporter as a function of external Na+ 
and substrate concentration, it is suggested that Na+ binds to the transporter first, and 
then the I- binds. A variety of anions are transported by NIS with varying affinities. 
These are: I-, ClO3-, SCN-, SeCN-, NO3-, Br-, BF4-, IO4-, BrO3-. From 
electrophysiological measurements and freeze fracture electron microscopy 
experiments, it is suggested that NIS may be multimeric in its functional form 
(Eskandari et al. 1998)  
 
1.1.1. The Role of Na+/I- Symporter  in Fight Against Thyroid Cancer 
As a result of NIS activity in thyroid, radioactive iodide treatment is an effective 
thyroid cancer therapy with minimal side effects. It was first used for thyroid cancer 
treatment in 1941 and became widely available after the second World War as a 
consequence of atomic energy research, leading to the birth of nuclear medicine 
(Sawin and Becker, et al. 1996). Among the most important clinical thyroid function 
tests in vivo is the thyroidal radioiodide uptake test (RAIU). The degree of 
accumulation of I-, as revealed by scans of the gland is used as an aid in the 
differential diagnosis of thyroid nodules. The possible existence of thyroid cancer is 
ruled out whenever a “hot” nodule is detected, since thyroid nodules that accumulate 
I- equally or more than the surrounding tissue are generally benign. However, the 
detection of a non I- accumulating (a “cold” nodule) increases the likelihood of 
thyroid cancer (Carrasco et al. 1993). The isotope 123I has a short half-life of 13 
hours and delivers a low dose of radiation in γ-range that is optimal for thyroid 
imaging. Another isotope, 131I, is primarily a β-emitter that has longer half-life (8 
days) and can deliver large amounts of radiation to thyroid tumor cells with little 
damage to surrounding tissues (Daniels and Haber, et al. 2000). Therefore, it is 
commonly used for radioactive ablation of benign overactive thyroid and of locally 
invasive or metastatic thyroid cancer.  
 To treat the cold nodules in thyroid, first these nodules are taken by surgery, 
and then RA is given to patient to induce dedifferentiation process in differentiated 
cold nodule cells. After this RA treatment patients are given radioactive iodide to get 
rid off residual cancer cells. 
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1.2. Iodide Transport in Mammary Gland 
1.2.1. Mammary Gland as an Organ 
Mammary gland development is one of the most fascinating and puzzling biological 
phenomena. Interestingly, the mammary gland seems to be the only organ that is not 
fully developed at birth (Tobon and Salazar et al. 1974). Although immaturity at 
birth can be assumed in most systems, no other organ presents such dramatic changes 
in size, shape, and function as does the breast, during growth, puberty, pregnancy, 
and lactation (Tobon and Salazar et al. 1974) 
 Prenatal development of the gland. Concerning prenatal and perinatal 
development of the mammary gland, it is established that the whole mammary 
parenchyma arises from a single epithelial ectodermal bud. Recent work of Kordon 
and Smith (1998) shows that any epithelial portion of a normal mouse mammary 
gland can reproduce an entire functional gland when transplanted into an epithelium-
free mammary fat pad. Moreover, they show that an entire functional mammary 
gland may comprise the progeny from a single cell (Kordon and Smith, 1998) 
 Formation of milk streak is first observed during the 4th week of embryonal 
life. This becomes the mammary ridge or milk line during the 5th week. Mammary 
ridge thickens, and forms milk hill stage at 6th week. By the 7th and 8th week 
parenchymal cells start to invade the underlying stroma, the mammary disk arises, 
progressing to a globular stage. Mammary parenchyma grows inward, and protrusion 
of the overlying skin regresses to form cone stage at the 9th week. Epithelial buds 
sprout from the invading parenchyma, which occurs between 10th and 12th weeks. 
With notching at epithelial-stromal border, buds become lobular between 12th and 
13th weeks. Branching stage starts between 13th and 20th weeks, by further branching 
into 15-25 epithelial strips or solid cords. Between 20th and 32th weeks, canalization 
stage occurs by desquamation and lysis of the central epithelial cells to canalize solid 
cords. Lobuloalveolar development occurs between 32 and 40 weeks of gestation, in 
which end vesicles are composed of a monolayer of epithelium and contain 
colostrum (Dabelow et al. 1957).  
Postnatal development of the gland. Postnatal period is very important for 
the completion of the development of a functional mammary gland. Postnatal 
development of the gland varies greatly from woman to woman, and makes it 
impossible to categorize mammary gland structure based on age. Mammary gland 
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development can be defined from the external appearance of the breast or by 
determination of mammary gland area, volume, degree of branching, or degree of 
structures whose appearance indicates the level of differentiation of the gland, such 
as lobule formation.(Dabelow et al. 1957) 
 The adolescent period begins with the first signs of sexual change at puberty 
and terminates with sexual maturity . Rudimentay mammae begin to grow both in 
glandular tissue and in the surrounding stroma with the approach of puberty. Small 
bundles of primary and secondary ducts grow and divide partly dichotomous basis. 
Ducts grow, divide and form clubshaped terminal end buds. These buds give origin 
to new branches, twigs, and alveolar buds. These buds are morphologically more 
developed than the terminal end bud, but more primitive than the ductules in mature 
organ. 
 Mammary gland development during pregnancy. Development of the gland 
in pregnancy can be divided into two main phases, early and late stages of pregnancy 
(Bassler et al. 1970; Salazar and Tobon et al. 1974). In the early stage, distal 
elements of the ductal tree proliferates, and grow forming acini by neoformation of 
ductules. By the third month of pregnancy, these well-formed lobules exceeds the 
number of primitive buds (Salazar and Tobon et al. 1974). The epithelial cells in 
each acinus is greatly increase in number, and in size (Salazar and Tobon et al. 
1974). At the mid-pregnancy, lobules become enlarged further and increased in 
number. In the second half of pregnancy branching continues in parallel with the 
formation of true secreting units. Proliferation of new acini  reduces to minimum, 
while secretory material begins to accumulate into luminae of acini, and at the end of  
pregnancy mature secretory acinus is formed. It is important to say that during these 
events there is still growing of undifferentiated area in glands.     
 Gestational changes. After postpartum withdrawal placental lactogen, and 
sex steroids lactation starts. No major morphological changes of the mammary gland 
are observed during lactation. As long as milk is removed regularly from the 
mammary gland, the alveolar cells continue to secrete milk almost indefinitely.  
 After weaning, a reduction in breast volume and secretary ability of epithelial 
cells is observed. Mammary lobules undergo atrophy, and stroma shows a marked 
desmoplastic reaction and fat infiltration. Cell autolysis, collapse of acinar structures, 
narrowing of the tubules, appearance of round cell infiltration, and phagocytes in and 
about disintegrating lobules occurs. Finally periductal and perilobular connective 
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tissue regeneration with renewed budding and terminal tubule proliferation occurs. 
(Salazar and Tobon, 1974). 
 
1.2.2 Hormonal Regulation of Mouse Mammary Gland Morphogenesis 
 Ductal growth is stimulated by various factors. One of them is estrogens. 
Estrogen receptors are concentrated in stromal cells around end buds not in rapidly 
dividing cap cells have role in stimulation of ductal growth. Another factor, EGF is a 
secondary mammotrophic signal acting on stromal cells for ductal growth. Stromal 
cells are also targets of a third hormone, growth hormone (GH). GH stimulates IGF-1 
synthesis in synergy with low doses of estrogen, and stimulate ductal growth in 
hypophysectomized animals (Kleinberg et al. 1997).  
   Prolactin (PRL) and progesterone (PR) are essential for labuloalveolar 
development. By PRL receptor-null epithelium transplantation to wild type virgin 
animal fat pads, it was observed that ducts developed normally, but at pregnancy 
labuloalveolar development is inhibited. PRL receptor is essential for targeting 
epithelial cells in labuloalveolar development (Brisken et al. 1999). Progesterone 
(PR) is another hormone found to have effects on labuloalveolar development. Loss 
of PR action caused ablation of lobuloalveolar development, while ductal 
morphogenesis seemed to be normal (Brisken et al. 1998). PR receptors are found 
exclusively in a subset of stem-type cells in the lumen of the duct (Silberstein et al. 
1996), and PR act by inter-epithelial, paracrine signaling (Brisken et al. 1998). 
 Not only growth stimulating factors but, also inhibitory factors play vital 
roles in mammary gland morphogenesis, by preventing infilling interductal space by 
lateral branching , and inhibiting of end bud extension at the fat pad boundaries, and 
TGFβ1 is one of these inhibitory factors (Silberstein et al. 1992). TGFβ family of 
growth factors inhibit proliferation and differentiation of target cells.  
Experiments done by ectopic expression of TGFβ in the mammary ducts, and 
mammary ducts with mutant TGFβR, it is found that TGFβ regulates lateral 
branching by acting on TGFβ receptors on stroma cells, by inhibiting HGF 
expression in the periductal extarcellular matrix (ECM ) (Joseph et al. 1999). It is 
found that site-specific inhibitory effect of TGFβ in lateral branching depends on 
TGFβ localization in mammary gland by ECM most probably via collagen-TGFβ 
binder decorin (Yamaguchi et al. 1990).   
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1.2.3 Identification of NIS in the Mammary Gland 
It has been known since the classical article of Honour published in 1952 that the 
breast also concentrates iodide, secreting it into milk (Honour et al. 1952). Nursing 
infants synthesize essential thyroid hormones using iodide from breast milk 
(Carrasco et al. 1993). A tragic consequence of iodide transport in mammary gland 
and thyroid cells was observed after the Chernobyl nuclear power plant accident in 
1986. In Ukraine and Belarus, this accident caused more than 800 children who 
drank milk from exposed dairy herds to develop thyroid cancers (Pacini et al., 1999). 
 
Two separate research groups addressed the question whether transporters 
responsible of I- transport in thyroid and in lactating mammary gland are identical, or 
two entirely different proteins. Immunoblots were performed on lactating mammary 
gland cell membrane fractions using antibodies (Ab) raised against thyroid NIS. 
These experiments have shown that Abs recognized a single band on immunoblots, 
albeit at a different molecular weight than the thyroid NIS. When the same 
experiment is repeated after treatment of membrane fractions from thyroid and 
lactating mammary gland with N-glycanase F enzyme (removing asparagine bound 
glycosyl residues), a single band at the same molecular weight is detected (Tazebay 
et al., 2000). This was a first evidence showing that these two proteins could be 
identical. Conclusive evidence about the identity of lactating mammary gland 
detected protein came from cyanogen bromide (CnBr) treatment of membrane 
fractions before the immunoblots. CnBr restricts proteins from the methionine 
residues, revealing an identical fragmentation pattern in identical proteins.CnBrn was  
cutting the NIS of thyroid and mammary gland at N terminus which had same 
glycosylation patterns. This was the result obtained for the NIS ab detected proteins 
in thyroid and mammary gland after treatment of membrane fractions from these two 
organs (Tazebay et al., 2000). Therefore, as previously suggested by Spitzweg et al. 
(1998) in result of their sequencing of NIS cDNAs from thyroid and lactating 
mammary gland cells, it was definitively shown that the Na+/I- Symporter that 
functions in the thyroid gland is also present in the lactating mammary gland 
(Tazebay et al., 2000; Cho et al., 2000).  
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1.2.4. Regulation of NIS in the Mammary Gland 
In healthy animals, mammary gland NIS (mgNIS) is expressed solely during 
lactation. Actually, the functional expression of mgNIS starts at mid-pregnancy (day 
11 of the 19 days gestation period in mice), and reaches the peak at end-pregnancy 
(day 18). Interestingly, after birth mgNIS expression is suckling-dependent in a 
reversible manner: when pups are separated from the mother for 24 hours, mgNIS 
expression drops significantly, and when they are re-united, again it increases 
(Tazebay et al., 2000; Cho et al., 2000). Based on these observations, in an effort to 
identify hormones responsible of mgNIS regulation, virgin mice (either 
ovariectomised or surgically unmodified) were treated with combinations of 
lactogenic hormones and steroids, and it was shown that 17-β-estradiol, prolactin, 
and oxytocin up-regulates functional NIS expression, whereas progesterone has a 
down-regulatory effect (Tazebay et al., 2000; Cho et al., 2000). Moreover, an 
increase in mgNIS protein expression in cultured mid-pregnant mammary gland 
explants is seen after 24 h PRL treatment. This study has shown that PRL increase 
NIS gene expression both at the transcriptional and  translational level (Rillema et al. 
2000).  
In a series of experiments using scintigraphic imaging accompanied with 
immunological techniques, mgNIS expression was also shown in mammary tumors 
of female transgenic mice carrying either activated Ras or Neu oncogenes under 
control of Murine Mammary Tumor Virus (MMTV) promoter. Significantly, these 
studies demonstrated functional mgNIS expression in both types of tumors (Tazebay 
et al., 2000). Subsequently, human breast specimens were examined by 
immunohistochemistry, and it was found that in contrast to no expression in 8 normal 
breast specimens from reductive mammoplasties, 20 out of 23 invasive carcinomas, 
and 5 out of 6 ductal carcinomas in situ did express mgNIS (Tazebay et al., 2000). 
This indicates that mgNIS is upregulated with a very high frequency during 
malignant transformation in human breast. This finding raised the question whether 
radioiodide could be effective for the diagnosis and as an adjuvant to surgical 
treatment of breast cancer, as it is the case in thyroid diseases. 
The hormonal regulation of NIS in mammary gland is studied, but cis-, and trans-
acting elements that are important in transcriptional regulation is unknown. 
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1.3. Regulation of Transcription in Eukaryotes 
1.3.1. A General Overview 
Most gene regulation occurs at the initiation of transcription. With a reductionist 
view, we can state that there are two types of genetic elements that help initiate or 
prevent this first step of gene expression: 1) cis-acting regulatory region in proximity 
of regulated genes; 2) trans-acting proteins (transcription factors) that interact with 
cis-acting regulatory regions. All regulated genes in eukaryotes contain two kinds of 
major cis-acting elements: The first one, the promoter, is always very close to the 
gene’s protein coding region. It includes an initiation site, where transcription begins, 
and a TATA box, consisting of roughly seven nucleotides of the sequence 
TATAA/TAT/A. This region is usually located 30 nucleotides upstream of the 
initiation site. The second type of elements, enhancers, are regulatory sites that can 
be quite distant –up to tens of thousand of nucleotides away– from the promoter. 
Enhancers are often called as “upstream activator sites” or UASs. The binding of 
trans-acting proteins (transcription factors) to a gene’s promoter or enhancer(s) 
controls the initiation of transcription. Different types of proteins bind to each of the 
cis-acting regulatory regions: Basal factors which assist recruitement of RNA 
Polymerase II (RNA Pol II) bind to the promoter, whereas activators and repressors 
bind to the enhancers (Kassavatis et al. 1990). When activator proteins bind to 
enhancer regions, they can interact directly or indirectly with basal factors at the 
promoter to cause an increase in transcriptional initiation (Mueller-Storm et al. 
1989). Another group of proteins that are shown to interact with transcriptional 
activators are chromatin remodelling enzymes such as histone acetyl transferases 
(HATs) and deacetylases (HAD), as well as SWI/SNF family of ATPases (see 
below). 
 DNA in eukaryotes are highly organized, and packed as chromatin. Basic 
structure of this packed DNA is nucleosome, which is a 146 bp of DNA wrapped 
twice around a histone core (Arents et al. 1991). This core is composed of two copies 
of histone H2A, H2B, H3, and H4 proteins. This wrapped DNA is then bound to 
histone H1 protein. In some parts of the genome, this packing is more condense as 
compared to other parts. More condensed regions are named as heterechromatins, 
and less condensed regions are called euchromatins. Heterchromatins are mostly 
untranscribed regions, while euchromatins are transcribed. In different cell types, 
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localization of euchromatin, and heterochromatin can change according to the 
transcribed genes (Felsenfeld et al. 1992). 
 In mammals, coactivator proteins that interact with transcription factors –or 
nuclear receptors, as called for hormone activated transcription factors– may be 
classified into two families of proteins: One family identified as proteins of 160 kDa, 
consists of related proteins: the steroid receptor coactivator proteins SRC-1A and 
SRC-1E (Kamei et al., 1996; Onate et al., 1995) transcription intermediary factor 
TIF2 (Voegel et al., 1996) also called as GRIP-1 (Hong et al., 1996), and CREB 
binding protein (CBP) interacting protein p/CIP (Torchia et al., 1997). The second 
family comprises CBP and p300, which were originally shown to function as 
coactivators for CREB, the transcription factor that mediates responses to protein 
kinase A stimulation. Subsequently, however, CBP/p300 were shown to function as 
coactivators for many other transcription factors and may play a central role in many 
signalling pathways (see below; Janknecht and Hunter, 1996); Shikama et al., 1997  
SRC-1 and p/CIP encode histone acetyl transferases (HATs) and they are capable 
of recruiting P/CAF, another histone acetyl transferase (Spencer et al., 1997; Yang et 
al., 1996). Therefore, they play a role in chromatin remodelling by acetylating 
histones. They may also play a role in the recruitment of the basal transcription 
machinery since CBP has been shown to interact with TFIIB (Parker et al., 1998)  
  
1.3.2. Regulation of NIS Transcription in Thyroid Gland 
Thyroid stimulating hormone (TSH) is the main hormonal regulator of thyroid 
function overall. This hormone is a glycoprotein of 30 kDa which is synthesized in 
the adenohypophysis by basophilic cells known as thyrotropes. Most actions of TSH 
take place through activation of adenylate cyclase via the GTP binding protein Gα 
(Vassart et al., 1995). The interaction of TSH with its receptor (TSHr) is necessary 
for the initiation of TSH related events in thyrocytes. Early observations made before 
the isolation of NIS cDNA suggested that TSH stimulation of thyroid I- accumulation 
results from the cAMP mediated increased biosynthesis of NIS (Kaminsky et al., 
1994). Later, using high affinity anti-NIS antibody, Levy et al. (1997) demonstrated 
that in rats NIS protein expression is upregulated by TSH in vivo. At around the same 
time, Kogai et al. (1997) has shown that TSH induces NIS gene mRNA expression 
as well. A detailed molecular mechanism leading to TSH regulation of NIS gene in 
thyrocytes was later proposed by Ohno et al. (1999) (see below). 
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 A through caracterization of the upstream enhancer of the rat thyroid NIS 
gene revealed that the regulatory region contains a basal promoter between –564 and 
–2 bp and an enhancer between –2,264 and –2,495 bp. This enhancer mediates 
thyroid specific gene expression by its interaction with two transcription factors; 
namely TTF-1 (Thyroid Transcription Factor-1) and Pax8. TTF-1 is a homeodomain 
region-containing transcription factor present in the developing thyroid, lung, 
forebrain and pituitary. Pax8 is an activator which is a member of the murine family 
of paired domain containing genes, and it is present in thyroid, kidney and 
developing midbrain. The interaction between Pax8 and the enhancer region of NIS 
gene is under control of a novel cAMP-dependent pathway (Ohno et al., 1999). 
Together with two Pax8 binding sites, this enhancer region contains two TTF-1 
binding sites and a degenerate CRE (5’-TGACGCA-3’)  sequence that is essential 
for the transcriptional activity. Both Pax8 and the unidentified CRE-like binding 
factor act synergistically to obtain full TSH/cAMP-dependent transcription. 
Interestingly, this enhancer is also able to mediate cAMP dependent transcription by 
a novel PKA-independent mechanism (Ohno et al., 1999). 
 
1.3.3. Regulation of Transcription by Estrogens, Retinoic Acids, and Prolactin 
1.3.3.1. Gene Regulation by Estrogens 
Estrogens are steroid hormones, which are mainly produced in ovaries, and testes.  
There are three main forms of estrogens, 17-β-estradiol, estriol, and estrone. 17-β-
estradiol is the most potent one among them. Estrogens diffuse into cells through 
membranes and bind to their intranuclear binding proteins (estrogen receptors) and 
regulate the expression of target genes by activating these receptors (Gronemeyer 
and Laudet et al. 1995). It is important to note that may also activate MAPK pathway 
via membrane bound G protein-coupled receptors (Filardo et al. 2000) 
 Estrogens have many effects on many tissues like mammary gland, uterus, 
vagina, ovary, testis, epididymis, prostate, bone, cardiovascular system, and central 
nervous system for growth, differentiation and function of these tissues (Clark et al. 
1992). 
 ERα and ERβ are the two types of estrogen receptors (ER) which are nuclear 
receptor superfamily members. ERα was first cloned in 1986 by Green et al., and 
after 10 years a second ER receptor, ERβ was cloned by Kuiper et al. (1996) and 
Mosselman et al. (1996). ERs can be subdivided into several functional domains 
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(Beato et al. 1995). A/B-region is highly variable in sequence and length, and usually 
contains a transactivation domain, which activates target genes by interacting with 
components of the core transcriptional machinery. C-region is DNA binding domain, 
and contains two zinc fingers which are important for specific DNA binding, and 
receptor dimerization. D-region is hinge domain, which gives flexibility to the 
receptors. E-region is ligand binding domain, and has role in ligand binding, receptor 
dimerization, nuclear localization, and interactions with transcriptional co-activators, 
and co-repressors. F-region is C-terminal extension domain and it contributes to the 
transactivation capacity of  the receptor.  
N  C 
A/B C  D  E  F 
Transactivation  DNA binding        Hinge domain  ligand binding       transactivation   
             
Rat ERα and ERβ  have %55 amino acid identity in their ligand binding 
domains, and %95 amino acid identity in their DNA binding domains. Two 
receptors’ ligand binding affinities, and specifities change from ligand to ligand 
(Barkhem et al. 1998). While two receptors have similar affinities to many ligands, 
17-β-estradiol, 17-α-ethynyl are ERα selective agonist, and 16-β, and 17-β-epiestriol 
are ERβ selective agonists. Additionally, two receptors responsed differentially to 
some antagonists. For example, tamoxifen, 4-OH-tamoxifen, raloxifene, and ICI 
164,384 have an ERα-selective partial agonist/antagonist function, but they are pure 
antagonists for ERβ (Barkhem et al. 1998). While they have some differences in 
binding and activation potencies to different ligands, both receptors have similar 
activating potencies at estrogen responsive element (ERE) sites .  
 Beside low homology in amino acid sequence, and ligand binding affinities 
of these two estrogen types, their tissue distribution is also different. In rat, while 
ERα  is mostly expressed in mammary gland, uterus, testis, pituitary, overy, kidney, 
epididymis, and adrenal , ERβ has a higher expression in mammary gland, prostate, 
ovary, lung, bladder, brain, and epididymis ( Kuiper et al.1996b).  
 
1.3.3.1.1 Transcriptional Activation Pathways of Estrogen Receptor 
It has been reported by Pettersson et al. in 1997 that ERα, and ERβ can form 
heterodimers in solution, or while they are bound to DNA. Heterodimer formation is 
greatly enhanced by the presence of a ligand.  
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 ERs use two mechanisms to activate target genes upon ligand binding. The 
first, and well known one is via binding to estrogen response elements (ERE) on 
promoters of target genes by its AF-2 domain, and the second one is via interacting 
with AP-1 sites or jun/fos proteins on AP-1 sites by its AF-1 domain. 
 An example to AF-1 domain activation of ERα, is tamoxifen partial agonism. 
Tamoxifen is one of the antagonists of ERα, and used as a chemo preventive agent 
for high breast cancer risk patients, and as a therapeutically agent in chemotherapy of 
breast cancer patients. But it was observed that tamoxifen therapy could cause 
endometrium, and uterus cancer (Kedar et al. 1994). Tamoxifen aganonism is 
defined first by Berry et al. in 1990, showing that tamoxifen binds to ER and allows 
ER to bind DNA. Then, AF-1 domain of ER and the target promoters get close to 
each other. In spite of weak transcriptional activity of  AF-1, it could activate target 
genes in three situations, cell type specificity, strong promoter specific activity, and 
MAPKK phosphorylation of AF-1 domain (Ali et al. 1993). Also ERβ possess a site 
in its amino terminus that is regulated by MAP kinases (Tremblay et al. 1997).  
Some genes that ER/AP1 pathway regulate are Insulin-like growth factor I, 
matrix metalloproteases, which have roles in cancer formation, and metastasis. ER 
action at AP1 responsive reporter genes correlate with tamoxifen, and estrogen 
effects on growth, since tamoxifen, and estrogen activate target genes by different 
mechanisms in cell type-specific manner via ER. 
  
1.3.3.2. Gene Regulation by Retinoic Acids 
Retinoids are both naturally occuring or synthetic vitamin A metabolites and analogs. 
Retinoids are essential for embryonic development, vision, reproduction, bone 
formation, metabolism, hematopoiesis, differentiation, proliferation and apoptosis 
(Gudas et al., 1994; DeLuca et al., 1991; Lotan et al., 1995; Nagy et al., 1998). 
 Retinoids bind to their receptors, and activate them to promote cell growth, 
differentiation, and apoptosis. Retinoid receptors belong to nuclear hormone receptor 
superfamily. These recptors have ligand binding domain (LBD) which is 
approximately 225 a.a., and DNA binding domain (DBD) which is approximately 66 
a.a. (Giguere et al. 1994). There are two types of retinoic acid receptors. These are 
RAR, and RXR receptors which are are activated by different ligands, while RARs 
are activated by both 9-cis, and all-trans retinoic acid (ATRA), RXR is activated by 
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only 9-cis RA. RARs, and RXRs are encoded by different genes and each type 
contains 3 subtypes α, β, and γ.  
Retinoic acid receptors activate target genes upon ligand binding, in 
dimerized forms. They can either form homodimers, or  heterodimers with each 
other. RXRs can also for dimmers with other nuclear receptors like thyroid hormone 
receptor. In the absence of ligand, retinoic acid receptors are bounded to co-repressor 
proteins like N-CoR or SMRT, mSin3, and histone deacetylases and they stay in an 
inactive state (Alland et al. 1997; Heinzel et. al., 1997; Nagy et al., 1997). Upon 
ligand binding, their conformation changes, and they bind to co-activator proteins 
like CBP/p300, and ACTR in order to mediate gene transcription (Freedman et al. 
1999).  
  
1.3.3.3 Gene Regulation by Prolactin 
 Prolactin (PRL) is an anterior pituitary hormone. It binds and activates 
prolactin receptor (PRLR) which belongs to a cytokine class-1 receptor superfamily 
(Taga et al. 1992). Rat PRLR has 3 main isoforms. These isoforms are short, 
intermediate, and long isoforms which are coded by alternatively spliced forms of 
PRLR transcripts(Goffin et al. 1996). In humans, a soluble PRLR was also 
identified, named as PRL binding protein (PRLbp) which does not have 
transmembrane, and cytoplasmic domain (Fuh  et al. 1995).  
Membrane-bound PRLRs contain three main domains, extracellular domain 
(ECD), transmembrane domain, and cytoplasmic domain (CD). ECD is composed of 
cytokine receptor homology region (CRH) which can be subdivided into D1, and D2 
domains, each showing analogies with the fibronectin type III module (Bazan et al. 
1990). PRL binding to its receptors is primarily driven by these conserved 
fibronectin type modules. Transmembrane domain contains 24 a.a. in rat PRLRs, and 
its functional activity is unknown yet. Intracellular domain of PRLR differs in 
isoforms of PRLR. In all isoforms of rat PRLRs, box1 region, which is membrane 
proximal region, is found. Box1 includes a 8 a.a. region which is enriched in prolines 
and hydrophobic residues, that are important for Janus kinase 2 (Jak2) association 
and activation (Goupille et al. 1997). Jak2 subsequently phosphorylates PRLR at 
tyrosine residues. After phosphorylation,  PRLR interacts with SH2 domains of 
STAT (Signal Transduction and Activation of Transcription); molecules which 
mediate cytokine and growth factor induced signals; and mediates STAT 
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phosphorylation, and thus activation. Phospho-STATs dimerize, enter to nucleus, and 
activates target genes which includes GAS (γ-IFN-activated sequence) sequences in 
their upstream regulatory regions. 
 Beside Jak2 pathway, PRLR also activates MAPK pathway, Src kinases, IRS-
1, SHP-2, PLC γ, PKC and intracellular Ca+2 (Bole-Feysot et al. 1998). 
 
1.4. Aim of Study 
Recent identification of NIS protein in the lactating mammary gland opened the path 
to many interesting studies. Some of the hormones that regulate NIS in mammary 
gland (mgNIS) were identified in previous studies (Cho et al., 2000; Tazebay et al., 
2000; Rillema et al., 2000). One question that still remains without an answer is the 
molecular determinants of mgNIS regulation. Which transcription factors regulate 
NIS expression in the mammary gland? Which cis-acting enhancer elements located 
in NIS upstream regulatory region interact with regulatory proteins? How does the 
chromatin structure in NIS regulatory region changes upon activation of this gene? 
 Some of the previously published studies indicated that estrogens may play a 
role in mgNIS regulation (Tazebay et al., 2000; Cho et al., 2000; Kogai et al., 2001). 
Yet, clear evidences showing the role of estrogen receptors in regulation of mgNIS 
are missing. Similarly, PRL was shown to be a hormone that upregulates mgNIS 
protein expression and iodide transport activity in various experimental settings, both 
in vivo and in vitro (Tazebay et al., 2000; Rillema et al., 2000). In this Master’s 
thesis project, we aimed to inquire 1) the contribution of estrogens to mgNIS 
regulation; 2) a possible role of human estrogen receptors α and β, as well as the 
prolactin receptor (PRLR) in mgNIS regulation in human mammary tumor cell lines 
in vitro. Insofar as NIS is functionally expressed to a sufficient degree in cancerous 
cells, whether of thyroid, breast, or any other origin, radioiodide emerges as a 
potential diagnostic and therapeutic tool. A considerable amount of work has already 
been carried out concerning transcriptional regulation of NIS in thyroid gland 
(Magliano et al., 2000). Yet, molecular determinants of mammary gland NIS 
transcription are entirely unknown. Therefore, besides its scientific impact, an 
extensive study of cis- and trans-acting factors regulating the NIS gene in mammary 
gland might prove extremely valuable and informative for the efforts of establishing 
novel diagnostic and/or therapeutic protocols against the breast cancer. 
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2.1. Bacterium Strain  
 The bacterial strain used in this study is DH5α which is a kind gift from Dr. 
Uğur Yavuzer from Department of Molecular Biology in Bilkent University. 
 
2.2. Growth And Maintenance Of Bacteria 
 Bacterial strains were stored as glycerol stock at –70 ºC. Glycerol stock was 
prepared by mixing 500 µl overnight grown cultures with 500 µl sterile glycerol, and 
keptat–70 ºC. Bacteria were recovered by growing some amount of stock in LB with 
an appropriate antibiotic at 37 ºC for 18 hours by shaking at approximately 190 rpm.  
 To grow bacteria on a solid medium, bacteria were spread onto LB agar, which 
contains appropriate amount of antibiotic.  
 
2.3. Mammalian Cells 
 We used MCF-7, and MDA-MB-231 breast cancer cell lines, CHO-K1 
Chinese hamster ovary cell line, and Hek-293 embryonic cell line. MCF-7, and 
CHO-K1 was taken from SAP Institute, MDA-MB-231 cell line was a kindly gift 
from Dr. Işık Yuluğ, and Hek-293 cells were a kindly gift from Dr. Mehmet Öztürk 
from Department of Molecular Biology and Genetics at Bilkent University 
 
2.4. Oligonucleotides 
All oligonucleotides were designed by using primer.exe program (Copyright 
1990,91 Scientific & Educational Software), and they were synthesized in 
Department of Molecular Biology at Bilkent University. All oligonucleotide 
sequences, and product lengths are given at table1.  
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Primer Pairs  Primer Sequence 
hERα 
 
(256 bp) 
F 
 
R 
 
5’-ATTCGGATCCT-CAAGGAGACTCGCTACTGTGC-3’
 
3’-ATCTCTCGAG-CATTCTCCCTCCTCTTCGGTC-3’ 
 
hNIS 
 
(602 bp) 
 
F 
 
R 
5’CTCATCCTGAACCAAGTGAC-3’ 
 
5’-GTGCTGAGGGTGCCACTGTA-3’ 
hGAPDH 
 
(142 bp) 
 
F 
 
R 
5’-GGCTGAGAACGGGAAGCTTGTCAT-3’ 
 
5’-CAGCCTTCTCCATGGTGGTGAAGA-3’ 
hPS2 
 
(389bp) 
F 
 
R 
5’-CCATGGAGAACAAGGTGATCTGC-3’ 
 
3’-GTCAATCTGTGTTGTGAGCCGAG-3’ 
 
rPRLR 
 
(1990 bp) 
F 
 
R 
 
5’-GATCCCGGAATTCAGTGCACAGCCTCTGGTATG 
GC-3’ 
3’-AAGGAAAAAAGCGGCCGCGTGAAAGGAGTGCA 
TGAAGC-3’ 
 
Table 1. The oligonucleotide sequences used in cloning and PCR experiments. 
 
 
2.5. Standard Solutions and Buffers 
 
LB Medium: 
10 g bacto-tryptone 
5 g yeast extract 
10 g NaCl 
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50X TAE Buffer: 
2 M Tris Base 
57.1 ml Glacial Acetic Acid 
50 mM EDTA 
    
10 X Phosphate-buffered Saline (PBS): 
80 g NaCl 
2 g KCl 
11.5 g Na2HPO4.7H2O                   
2 g KH2PO4o 
 
2X SDS PAGE Loading Buffer: 
1 ml 0.5 M  Tris-HCl pH 6.8 
0.8 ml glyserol 
1.6 ml 10% SDS 
0.4 ml 2-Beta-MercaptoEthanol 
0.4 ml 0.05% Bromophenol Blue 
3.8 ml ddH2O 
 
Transfer Buffer: 
25 mM Tris 
192 mM Glysine 
10% Methanol 
 
1X TE: 
10 mM Tris, pH 8.0 
1 mM EDTA, pH 8.0 
 
Bradford Solution: 
Stock solution  (15 ml)                                                        Working Solution (100 ml) 
5 ml 95% Ethanol                                                                     85.15 ml ddH2O 
10 ml 85% Phosphoric Acid                                                    2.85 ml 95% Ethanol       
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17.5 mg Coomassie Brilliant Blue                                           3 ml Phosphoric Acid 
                                                                                                 3 ml Bradford stock     
5X Tris-Glycine Electrophoresis Buffer: 
22.5 g Tris 
108 g Glycine 
7.5 g SDS 
Adjust volume to 1 L 
 
 
TBS: 
100 mM Tris (pH 7.5) 
500 mM NaCl 
 
 
 
2.6. Recombinant DNA Techniques: 
2.6.1. Polymerase Chain Reaction 
 Polymerase chain reaction (PCR), is a rapid procedure for in vitro enzymatic 
amplification of specific sequence of DNA (Mullis and Faloona et al. 1987), was 
performed to amplify the partial coding sequences of hER-α, hPS2, hGAPDH, and 
hNIS genes, and complete mRNA coding region of rPRLR gene. PCR reactions were 
all performed in 0.2 ml ThermowellTM  tubes (Corning Costar Corp.) using the 
GeneAmp PCR system 9600 (Perkin Elmer). 
 All PCR reactions were performed in final volume of 25 µl, containing 1-2 ng of 
template genomic DNA, or 1 µl cDNA , 1X  PCR buffer (MBI Fermentas), 1.5 mM 
MgCl2 (MBI Fermentas), 0.2 mM of each dNTP (MBI Fermentas), 10 pmol of each  
primer except hGAPDH primers which were used 5 pmol, and 1 unit Taq DNA 
polymerase (MBI Fermentas). 
 The reaction was preheated to 94 ºC for 5 minutes, and then subjected to 30 cyles 
of denaturation (30 seconds at 95 ºC for all except rPRLR, it was 40 seconds for 
rPRLR), annealing (40 seconds at 60 ºC for hNIS,  hGAPDH, hPS2primers, 40 
seconds at 50 ºC for ER-α, and 30 seconds at 58 ºC .), and elongation (at 70 ºC for 40 
seconds for hNIS, hGAPDH, hPS2, hER-α, and 50 seconds for rPRLR primers ). At 
the end of 30 cycles a final extension at 72 ºC for 10 minutes was also applied. 
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Agarose gel electrophoresis and Ethidium Bromide (EtBr) staining assessed 20 µl of 
the PCR products.  
2.6.2.Semi-quantitative PCR  
  Semi-quantitative PCR is a suitable method for comparing the relative 
amount of the used templates between different samples. Normally, the PCR reaction 
does not have a linear graph for the product amount versus cycle number. In 
algebraic terms, it is the graph of the combination of two functions. This is due to the 
saturation of the PCR. In order to have a dependable comparison, the cycle number, 
in which the PCR reaction is not saturated, should be determined for each gene. This 
was done by performing the PCR reaction for different cycles for each gene, and 
drawing a graph from the intensity of the DNA bands assessed by agarose gel 
electrophoresis. Optimized cycle numbers for pS2 was 23, for GAPDH was 19, and 
for NIS was 27. 
 
2.6.3. Purification of DNA Fragments by Agarose Gel Electrophoresis 
  DNA purification from agarose gel is performed by Qiagen Gel Purification 
Kit according to manufacturer’s manual after running the PCR products on agarose 
gel, and cutting the desired band from agarose gel.  
 
2.6.4. Restriction Enzyme Digestion of DNA 
 1-5 µg DNA was digested with appropriate amount of buffer and units of 
enzyme in a 20 ml final volume according to the manufacturer’s recommendations at 
16 ºC for overnight. 
 
2.6.5. DNA Ligation 
  DNA fragments were ligated with plasmid vectors according to the protocol 
described in Molecular Cloning (Maniatis et al. 1982). Prior to ligation vector and 
insert concentrations are checked by agarose gel electrophoresis. For directional 
cloning, vector:insert ratio was kept close to 1 in the ligation reactions. Ligations 
were performed in 15 µl reaction volumes containing approximately 0.1-0.2 µg of 
plasmid DNA, and the corresponding amount of insert in the presence of 4 Weiss 
units of T4 DNA ligase, 1mM ATP, and standard ligation buffer, supplied by the 
manufacturer. The reaction was performed at 16 ºC for overnight. 
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2.6.6. Plasmids 
 Plasmids that are used in this study are, ERα-pSG5puro,ERE-bglob-Luc      .        
were kindly provided by Dr. Ediz Demirpence, and pcDNA3.1c  was kindly provided 
by Dr. Uğur Yavuzer. 
 
2.6.7. Recombinant Expression Constructs 
 rPRLR-pcDNA-3.myc-his  
            Erα-pcDNA3.1c 
2.7. Preparation Of Competent Cells And Transformation Of E.coli 
2.7.1. Simple and Efficient Method (SEM) 
 A single colony of DH5α was inoculated into 15 ml of LB, and grown 
overnight. The starter culture was diluted to an O.D.600 of 0.2-0.3 in 250 ml of SOB 
medium (2% Bacto-tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCL, 10 
mM MgCl2, 10 mM MgSO4, sterilized through autoclaving), and grown to an OD600 
of 0.6 at 18 ºC with shaking at 200 rpm. The culture was chilled on ice for 10 
minutes, centrifuged at 2500 g for 10 minutes at 4 ºC. The pellet was then 
resuspended in 80 ml of ice-cold TB (10 mM Pipes, 55 mM MnCl2, 15 mM CaCl2, 
250 mM KCL, pH 6.7, sterilized by filtration through 0.45 um filter, stored at 4ºC), 
and incubated on ice for 10 minutes. The mixture was precipitated as above, 
resuspended gently in 20 ml of TB. DMSO was added to a final concentration of 7%, 
mixed gently and incubated on ice for 10 minutes. 500 µl aliquots of this mixture 
were then immediately frozen in liquid nitrogen, and stored at –70 ºC up to 3 months 
without loss of transformation efficiency (Inoue et al. 1990) 
 
2.7.2. Transformation of E.coli 
With super-competent cells (look to 7.1), 0.1 µg plasmid DNA is sufficient 
for high transformation efficiency. 0.1-0.5 µg of plasmid DNA was  mixed with 200 
µl supercompetent cells, and incubated on ice for half an hour in a 15 ml round 
bottom tube (Greiner Labortechnik). Then the cells were heat shocked at 42 ºC  for 
30 seconds, chilled on ice for 2 minutes, and then grown at 37 ºC for 1 hour at 200 
rpm, after adding 0.8 ml of SOC (SOB with 20 mM glucose) onto them . After 1 
hour, 50 µl of culture was spread onto LB agar plates containing appropriate 
antibiotics. (Inoue et al. 1990) 
 
 24
 
2.8. Plasmid DNA Isolation 
2.8.1. Small Scale Plasmid DNA Isolation 
 Single colonies were picked up from LB plate, and inoculated in LB with 
appropriate antibiotic in an 15 ml falcon tube. Culture was grown overnight at 37 ºC 
with shaking at 160 rpm. 1.5 ml culture was taken into an eppendorf tube andcells 
were precipitated. Supernatant was discarded, and the pellet was dissolved in 150 µl 
Solution I (50 mM Glucose; 25 mM Tris.Cl pH8.0; and 10 mM EDTA pH8.0) by 
vortex. Freshly prepared 200 µl Solution II (0.2 N NaOH; 1% SDS) was added 
immediately and mixed by inversion for 5 times. 150 µl Solution III (60 ml 5M 
potassium acetate, 11.5 ml glacial acetic acid, 28.5 ml H2O=100ml) was added 
immediately and mixed by inversion 5 times. The mixture was centrifuged for 5 
minutes at 16,249 xg, and the supernatant was transferred to a clean eppendorf tube. 
400 µl phenol:chlorophorm (24:1) mixture was added and vortexed for 1 minutes and 
centrifuged for 5min at 16,249 xg. The upper layer was transferred to a new tube and 
800 µl ice cold absolute ethanol was added and mixed by inversion. Mixture was 
centrifuged at 18,845 xg for 20 minutes at 4ºC. The EtOH was removed and the 
pellet was washed with 70% EtOH and dried at RT. The pellet was dissolved in 
appropriate amount of water.   
 
2.8.2. Medium Scale Plasmid DNA Isolation 
 Positive bacteria colony which was screened after miniprep was grown in 100 
ml LB with appropriate amount of antibiotic overnight. To perform midiprep, the 
Nucleobond AX-100 kit (Macherey-Nagel) was used. The culture was spinned down 
at 6000 rpm for 3 minutes in 50 ml falcons. Supernatant was discarded and cell pellet 
was dissolved with 4 ml S1 buffer. 4 ml S2 was added and mixed by inversion for 5 
times. Immediately 4 ml S3 buffer was added and mixed by inversion, and filtered by 
filter paper immediately. After equilibration of the cartridges with 2.5 N2 buffer, 
filtered suspension was loaded onto cartridge. After elution, cartridge was washed 
with 5 ml N3 buffer 2 times. The plasmid DNA was eluted with 5 ml N5 buffer in a 
clean polypropylene centrifuge tube. 3.6 ml isopropanol was added and mixed. 
Centrifugation was performed by  centrifuge for 30 min at 20,000 g. The supernatant 
was discarded, and the plasmid DNA pellet was washed with 70% (ethanol) EtOH 
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for 3 times. The pellet was dried and dissolved in an appropriate amount of sterile 
ddH2O. 
 
2.8.3. Spectrophotometric Quantification of DNA 
 5 µl of each sample was diluted in 1:200 ratio with sterile ddH2O. With 
spectrophotometer (Beckman), O.D. measurements were done at 260 and 280 nm. 
O.D. 260/ O.D.280 ratios were calculated inorder to understand if there was any 
protein contamination. The expected ratio was between 1.6-2.0.   
 
2.9. Cell Culture Techniques  
2.9.1. Thawing a frozen Cell Line 
 Frozen cell line stock was transferred from liquid nitrogen tank to 4 ºC, and 
taken immediately to 37ºC water bath. After it was completely dissolved, it was 
diluted in growing medium, and centrifuged for 4 minutes at 400 rpm. After 
centrifugation the supernatant was aspirated, and the cell pellet was gently 
resuspended with growing medium, and plated on desired plate, or flask. The culture 
was incubated at 37ºC, in a humidified chamber with 5% CO2.  
 
2.9.2. Sub-Culturing of Monolayer Cells 
 After cells reached to 80-90 % confluency, they were subcultured into new 
plates, or flasks. Medium of cells was aspirated, and then cells were washed with 1X 
PBS two times before putting 1 ml trypsin-EDTA to 10 cm plates. Cells were 
incubated with trypsin-EDTA at 37 ºC for 3 minutes, and after all were detached, 
they were mixed with 5 ml growing medium, and split into fresh plates or flasks at 
desired ratio, and were grown at 37 ºC humidified chamber with 5% CO2.  
 
2.9.3. Cryopreservation 
 Cells were detached from the plates by trypsin as told above, and after this 
step, cells were collected in a falcon tube, and centrifuged at 400 rpm for 4 minutes. 
After that the supernatant was aspirated , and the cell pellet was dissolved in frozen 
medium in a 5 millions of cells/1 ml frozen medium ratio. Then this mixture was put 
into cryotubes, and were frozen overnight at –80 ºC from where transferred into 
liquid nitrogen (Doyle and Griffiths et al. 1997). 
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2.9.4. Transient Transfections 
Two transfection methods were used.  
 
2.9.4.1. Electroporation 
Cells were splitted 18 hours prior to transfection. The confluence of cells were 90% 
at the time of transfection. Cells were trypsinized, collected and counted. 
Appropriate amount of cells 15 X106/cuvette centrifuged at 400 g for 5 minutes. 
Medium was aspirated, and cells were washed with 10 ml Ca+2, Mg+2 free 1X PBS, 
and centrifuged at 400 g for 5 minutes. Washing was repeated once more. Cell pellet 
was dissolved in appropriate amount of Ca+2, Mg+2 free 1X PBS (800 ml/cuvette). 
800 ml cell suspension was put into an ice cold electrophorese cuvette. 40 µg 
plasmid DNA was added onto the cells, mixed, and incubated on ice for 5 min. The 
cuvette was placed into the electrophoresis machine, and electric pulse was given for 
18-22 seconds, at 220 mV, and 950 µF setted apparatus. Cuvettes were incubated on 
ice for 5 min, and transfected cells were plated onto two 15 cm plates.  
 
 
 
2.9.4.2. CaCl2 Transfection 
Cells were splitted 18 hours prior to transfection, and the confluency was between 
50-70% at the time of transfection. 20 µg plasmid DNA was mixed with sterile 
ddH2O to a final volume of 450 µl in a 15 ml falcon tube. During vortexing the 
falcon, 50 µl 2.5 M CaCl2 was added drop by drop. The mixture was incubated for 30 
min at RT. 500 µl of BES pH 6.95 (for some cell lines pH optimization was required) 
was added during vortexing the mixture in falcon. The final solution was incubated 
at RT for 40 min, and 1 ml from this solution was added onto cells with 9 ml medium 
drop by drop. 12-18 hours after transfection cells were washed with 1X PBS for 3 
times and fresh medium was added.   
 
2.9.5. Stable Transfection 
72 hours after transfection of mammalian cell lines with 10% confluency, antibiotic 
selection was started. After 2-3 weeks of selection colonies were formed, and with 
sterile pipette tips they were picked up and plated onto 96 well plates. Then they 
were plated onto 24 well plates, 12 well plates, 6 well  plates, and 10 cm plates 
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respectively. They were frozen immediately after protein isolation from each colony. 
By western blotting each colony was screened for positive expression of desired 
exogenous gene. 
 
2.9.6. Cell Treatments 
2.9.6.1. Culturing Cells in  Media 
Minimal Media: MM, DMEM without phenol red containing 3% charcoal treated 
FBS, and 1% P/S 
Normal growth media: NGM, DMEM with phenol red containing 10% FBS, and 1% 
P/S 
Cells were grown in minimal medium, which is DMEM without phenol red 
containing 3% charcoal treated FBS(fetal bovine serum), and 1% P/S (penicillin/ 
streptomycin), for 1-2 weeks to get rid of the steroids and phenol red in media, and in 
cells.   
2.9.6.2. Treatment of Cells with Various Substances  
 Cells were treated with various substances. All the substances were powder, 
and dissolved in 95% (ethanol) EtOH as a 10-2 M stock solutions. The stocks were 
diluted into final concentrations, by diluting them in medium. 
 
2.10. Gel Electrophoresis 
2.10.1. SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 To separate proteins with different masses in denaturing conditions by 
electrophoresis SDS-page is used according to the following method described in 
Current Protocols (Ausucel 1987).  All SDS-pages in this study was prepared by 
using Thermo EC mini vertical GEL system. The apparatus was prepared according 
to the instructions described by manufacture. 10% resolving gel was used, and both 
resolving gel and stacking gel is prepared by 30% acrylamide stock solution. 10 ml 
10% resolving gel is prepared by mixing 5 ml 30% acrylamide (29,2% acrylamide, 
0.8% bisacrylamide), 2.5 ml 1.5 M Tris pH 8.8, 50 µl 20% SDS, 100 µl 10% 
ammonium persulfate, and 4 µl Temed, and poured into the gap between glass plates, 
and immediately iso-propanol was poured onto resolving gel to give a sharp edge. 
After polymerization 5ml stacking gel was prepared by mixing 0.83 ml 30% 
acrylamide (29,2% acrylamide, 0.8% bisacrylamide), 0.63 ml 1M Tris pH 6.8, 50 µl 
10% SDS, 50 µl 10% ammonium persulfate, and 5 µl Temed, and poured onto 
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washed resolving gel with ddH2O. And immediately avoiding not forming bubbles 
the comb was placed. After polymerization comb was taken out, and the wells were 
washed with running buffer to get rid off unpolymerized gel.  
Protein samples with appropriate amount (30-40 µg), are mixed with 5X SDS 
loading buffer and incubated in boiling water for  5 min, or at 70 ºC for 10 min. 
These samples were incubated on ice for 5 min and loaded onto gel. Gel was run at 
80 V until samples run to resolving gel, after the voltage was increased to 100 V. 
After running proteins were transferred onto an appropriate membrane. 
 
2.11. Biochemical Techniques 
2.11.1. RNA Isolation From Mammalian Tissue Culture Cell Lines 
RNA isolation from cells was performed by acid guanidinium thiocynate-phenol-
chloroform extraction method . 0.1 g tissue was homogenized with 1 ml solution D 
(4 M guanidinium thiocyanate; 25 mM sodium citrate pH 7; 0.5% sarcosyl; 0.1 M 2-
mercaptoethanol)(cells in 10 cm plate was lysed with 1 ml solution D). 0.1 ml 2M 
sodium acetate pH 4 was added, mixed by inversion, then 1 ml phenol was added and 
vortexed. 0,2 ml chloroform-isoamyl alcohol (49:1) was added, vortexed and 
incubated on ice for 15 minutes. The mixture was centrifuged at 10,000 g for 20 min 
at 4 ºC. Aqueous layer was transferred into new tube, and mixed with 1 ml 
isopropanol and incubated at –20 ºC for 1 hour. The mixture was centrifuged at 
10,000 g for 20 min at 4 ºC, and supernatant was removed. The RNA pellet was 
washed with 70% (ethanol) EtOH for 3 times, and dried at RT. The pellet was 
dissolved in DEPC treated ddH2O 
 
2.11.1.1. RNA quantification 
  5 µl of each sample was diluted in 1:200 ratio with sterile ddH2O, and with 
spectrophotometer (Beckman) O.D. measurements were done at 260 and 280 nm. 
 Concentration of RNA was calculated with this formula: 
  [RNA]=O.D.260Xdilution factor(200)X40 
 O.D. 260/ O.D.280 ratios were calculated in order to understand if there was any 
protein contamination. The expected ratio was between 1.6-2.0.   
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2.11.1.2. RT-PCR: 
  The cDNA samples were synthesized from the total RNA samples with the 
RevertAid First Strand cDNA Synthesis Kit (MBI Fermentas) by using the 
manufacturer’s protocol. 
 5 µg of RNA was mixed with 1 µl random hexamer primer, and mixed with 
appropriate amount of deinozed water in a final volume of 12 µl. The mixture was 
incubated at 70 ºC for 5 minutes, and chilled on ice. After quick spin, 4 µl of 5X 
reaction buffer, 1 µl of RNase inhibitor, 2 µl of 10 mM dNTP mix was added 
respectively and incubated at 25 ºC for 5 min, and 1 µl of RevertAid M-MuLV 
reverse transcriptase was added and incubated at 42 ºC for 1 hour. Incubating the 
mixture at 70 ºC for 10 minutes, the reaction was stopped. 
 
2.11.2. Protein Isolation from Whole Cell Extracts 
2.11.2.1 Eukaryotic Cell Lysis 
 After aspirating medium, cells were washed with cold 1X PBS two times. 1 ml 
cold 1X PBS was put onto cells, and on ice all cells were scraped, and cell 
suspension was collected into 1.5 ml eppendorf tube. Cells were precipitated  at 4 ºC. 
PBS was aspirated and cells were frozen in liquid nitrogen and stored at –80 ºC. 4X 
w/m lysis buffer was put onto cells, the cell pellet was dissolved by gentle mixing, 
and waited on ice for 30 minutes. Mixture is mixed gently by 10 minute periods. 
Mixture was centrifuged at 116,249 xg for 20 minutes 4 ºC. Supernatant was 
aliquoted as total protein sample.  
 
2.11.2.2. Bradford Assay 
 Protein concentration was determined by Bradford assay. Bovine serum 
albumin (BSA) was used as protein standard and the standard curve was calculated 
by taking OD595 of different BSA concentrations from 2,5 µg/ml to 20 µg/ml mixed 
with Bradford working solution. 5 µl of protein samples were mixed with Bradford 
working solutions and OD595 was measured and concentration of these protein 
samples was calculated by standard BSA curve. 
 
2.11.3. Immunological Detection of Immobilized Proteins  
2.11.3.1. Transfer of Proteins onto Membranes 
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  Semi-dry transfer of proteins from SDS-PAGE gel to PVDF membrane was 
performed by semi-dry transfer machine. Whatman papers and membrane was 
prepared by cutting them on the same size as the resolving part of gel. Membrane 
was waited in methanol for 30 sec, then washed with transfer buffer and incubated 
with whatman papers in transfer buffer for 5 min. 3 whatman papers were placed on 
the transfer apparatus, onto them the nitrocellulose membrane was placed, and then 
the gel was placed and 3 whatman papers were placed on the gel. Bubbles should not 
be formed, to avoid this a cylinder was used. After closing the apparatus the transfer 
was obtained at 12 V for 30 min. If 2 gels were used , then 50 min should be applied.  
 
2.11.3.2. Detection of Immobilized Proteins 
After transfer of proteins to nitrocellulose membrane, membrane was incubated 
in blocking solution (TBS-T, 3% dried milk) for 1 hour at room temperature or 
overnight at 4 ºC. Then membrane was washed with TBS-T for 5 minutes at RT three 
times. After wash, membrane was incubated with 1st antibody, which was diluted in 
blocking solution (1:1000 dilution for c-myc, 1:500 dilution for ER-α, and 1:100    
dilution for ER-β) for 1 hour at RT, or overnight at 4 ºC. Membrane was washed 
with TBS-T for 5 minutes at RT three times. And the membrane was incubated with 
2nd antibody which is diluted in blocking solution ( 3% dried milk in TBS-T) at RT 
for 1 hour . The membrane was washed with TBS-T for 5 minutes three times. Using 
Amersham LIFE SCIENCE ECL Western blotting detection reagents according to 
the manufacturer’s instructions carried out the immunodetection with HRP 
conjugated secondary antibody. The bands were visualized by exposing the 
membrane on photograph films.  
2.11.4. Luciferase Assay 
 5X105 cells were plated on 6 well plates 18 h prior to transfection. Transfection was 
performed by calcium phosphate  method (Look to 9.4.2.). 20 µg plasmid DNA was 
transfected to the cells in each well. 24 h after transfection, cells were treated with 
desired substances (17-est in our case) for 36 hours. Luciferase assay was performed 
according to manufacture’s instructions.   
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2.11.5. Southern Blot 
2.11.5.1.Genomic DNA digestion and membrane blotting 
Genomic DNAs (8 µg) were digested with 4 units of BglII overnight at 37°C in a 
final volume of 50 µl. Then the digests were run on a 1% agarose gel in TAE buffer. 
Running is performed at 50V for 7 hours. The gel is then put into the denaturation 
solution 1.5 M NaCl, 0.5 M NaOH for 30 min. Then it is placed into the renaturation 
solution, which was 1.5 M NaCl, 0.5 M Tris-HCl pH: 7.2, EDTA 10 mM. The gel is 
left in this solution for 30 min, with constant shaking at 100 rpm on a bench-top 
shaker. The gel was carefully put on the whatman paper and the area covering the gel 
is surrounded by saran wrap to avoid leaks from this region due to capillary forces. A 
nylon membrane (Hybond-N, Amersham) of precisely the size of the gel was put on 
top of the gel and covered with two pieces of 3MM whatman paper and enough 
tissue papers on top. The stack was pressed with a book of around 500g on a glass 
plate. After disassembly of the stack, the positions of the wells on the membrane 
were marked with a pencil. Upper left edge of the membrane was cut off to allow 
easy orientation. The membrane is the removed, and air dried for 10 minutes. Then 
the DNA is fixed on membrane by U.V. using a Stratalinker (Stratagene, CA) 
apparatus.  
 
2.11.5.2. Labelling the DNA probe 
A DNA fragment corresponding to the EcoRI-BglII fragment (1286 bp) of human 
ERα gene is cut and purified from a 0.8% agarose gel. 50 ng of linearized DNA is 
taken in 20 µl ddH2O and denatured by incubation in boiling waterbath. The 
labelling was performed with a Random Prime DNA labelling kit. The reaction 
carried out by adding 2µl dNTP mix solution (0.5 mM each nucleotide) 2 µl random 
hexanucleotide solution, 6 µl radioactively labelled nucleotide (α32P-dCTP; specific 
act. 10 mCi/ml), 10 µl ddH2O and 1µl Klenow enzyme (2U/µl). The reaction was 
carried out for 30 min at 37°C. To remove unincorporated nucleotides from the DNA 
probe, labelled samples was purified using G-50 Sephadex quickSpinTM columns, 
using the manufacturers instructions. Specific activity of 1µl (out of around 40µl) of 
probe is measured with a radioactivity counter, and the probe is used in hybridization 
reaction.  
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Labelling is done twice. Specific activities were as follows: probe 1: 4,6x105 cpm; 
probe 2: 5,5x105 cpm. Probe 2 was used in experiment shown in this thesis. 
 
2.11.5.3. Hybridization with a labelled probe 
The membrane is prehybridized in a hybond cylinder and oven for 3 hours at 65°C in 
a buffer containing 0.5 M Na2HPO4 pH: 7.0, 1 mM EDTA, 7% SDS, 1% BSA. Then 
the radioactively labelled probe is denatured in boiling waterbath for 5 min and it is 
added in prehybridization solution. Hybridization is performed for 14 hours. Then, 
the membrane is washed once at RT with 2x SSC, 0.2 SDS for 15 min, and twice at 
65°C in 0.2x SSC, 0.1 SDS. Afterwards, the membrane is wrapped in saran wrap and 
exposed to an autoradiography film for overnight. 
 
2.11.6 Semiquantitative PCR optimization 
 In order to perform semi-quantitative PCR reactions, we first to optimize the 
cycle numbers for pS2, hNIS, hGAPDH. Seen below. 
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3. RESULTS 
3.1. Introduction 
 Hormonal regulation of mammary gland NIS (mgNIS) was previously 
studied and the roles of estrogen (17-β-estradiol), oxytocin, prolactin, and 
progesterone on regulation of mgNIS expression or activity was established 
(Tazebay et al., 2000, Cho et al., 2000, and Rillema et al., 2000). It is important to 
state that among the hormones tested in these studies, 17-β-estradiol (17-Est) is the 
only one that activates mgNIS protein expression in mammary when administered 
alone to overiectomized virgin mice (Tazebay et al., 2000). The effect of oxytocin on 
mgNIS was surprising: this hormone does not activate mgNIS expression in 
ovariectomized mice, but it does so in animals that are not surgically modified, i.e. 
animals with intact ovaries (Tazebay et al., 2000, Cho et al., 2000). Moreover, a 
decrease in radioiodide uptake in lactating mammary glands after treatment with an 
oxytocin inhibitor, and an increase in hNIS mRNA after oxytocin treatment of 3-D 
histo-cultures of human breast tumors were also demonstrated (Cho et al. 2000). 
Prolactin is another hormone that is shown to activate mgNIS expression when 
administered together with oxytocin, and estrogen in overiectomized virgin mice 
(Tazebay et al. 2000). Also in cultured mouse mammary tissues, prolactin was 
shown to stimulate mgNIS expression (Rillema et al. 2000).  
 Above summarized studies have identified several hormones that may 
contribute to mgNIS regulation in animal models. Next logical step in analysis of 
mgNIS gene regulation is going to be the identification of cis- and trans-acting 
elements responsible of the regulation of this gene in the mammary gland. In this 
study, we aimed to focus on several candidate trans-acting factors, such as estrogen 
receptors, and candidate signalling pathways such as the prolactin receptor/Stat5 
signalling pathway, and to assess their possible contribution to this regulation in in 
vitro conditions.  
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Fig. 1.  ERα status of MCF-7, and MDA-MB-231 cell lines.  Total protein was 
isolated from MCF-7 and MDA-MB-231 cell lines and a Western blot analysis was 
performed using monoclonal anti-human ERα Ab. ERα protein is detected in MCF-7 
cell line (indicated with arrowhead), whereas it is not detected in MDA-MB-231 cell 
lines. M, is a size marker; sizes indicated with arrowheads. 
 
   
3.2. The effect of retinoic acid on NIS gene expression in MCF-7 human 
mammary cancer cell line. 
Despite a very broad and time consuming search by several groups, only one 
mammary gland cell line was, so far, identified to express mgNIS mRNA and protein 
in an inducible manner. This is the estrogen receptor positive [ER(+)] MCF-7 human 
mammary gland cancer cell line (Kogai et al., 2001). In this cell line, mgNIS was 
shown to be inducible by retinoic acid (RA), a ligand that was known to induce the 
iodide transport activity in dedifferentiated thyroid tumor metastatic tissues in 
humans (Schmutzler and Kohrle, 2000; Kogai et al., 2001). In the study of Kogai et 
al. (2001), mgNIS mRNA levels were highest after treatment with 10-6 M RA for 24 
hours. The absence of a similar increase in mgNIS mRNA levels in ER(-) MDA-
MB-231 cell line after a similar treatment led them propose that the ERs may have a 
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role in this regulation of the iodide transporter gene under these conditions (Kogai et 
al., 2001). In an effort to study a possible role of ERs in mgNIS regulation, we 
decided to use the same experimental system, and inquire about the role of these 
transcription factors (ERs) in mgNIS regulation.  
We have started our experiments by checking the ERα status of mammary 
cell lines used in the study of Kogai et al. (2001). This has confirmed the ERα(-) 
phenotype of the MDA-MB-231 cell line, and the ERα(+) phenotype of the MCF-7 
cell line (Fig. 1). Then we have repeated the RA treatment of MCF-7 cell lines, 
simply to check the reported effect of RA on these cell lines in our laboratory 
conditions. By RT-PCR, we observed the expression of mgNIS mRNA in MCF-7 
cells after  24h, and 48h RA treatments as Kogai et al.(2001)(Fig. 2). There were no 
amplification without RA treatment, similar to what was observed in the study 
performed by Kogai et al. (2001).(Fig. 2.) 
  
 
 
 
 
 
 
  
 
Fig. 2. Response of the mgNIS gene to RA treatment. MDA-MB-231, and MCF-7 
cells are treated with 10-6 M RA in DMEM growth medium (DMEM (including 
phenol red) + 10% FBS + 1% P/S) for indicated time periods. RT-PCR is made from 
total RNA by using hNIS, hGAPDH, and hPS2 primers (see Materials and Methods). 
House keeping gene GAPDH is used as a control of RT-PCR amplification. PS2 is 
an estrogen responsive gene of unknown function (Jakowlew et al. 1984), and it is 
used as a control of ER activity. 
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3.3. RA treatment of MCF-7 cells grown in minimal media. 
 In order to perform semi-quantitative PCR reactions to detect mRNA level 
differencies, we first optimized the cycle numbers for pS2, hNIS, hGAPDH. Seen 
below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Graph. 1. Semi-quantitative optimization of GAPDH, PS2, and NIS primers. 
For GAPDH, cycle 19, for NIS cycle 27, for pS2 cycle 23 is chosed. 
Phenol red that is present in most cell culture medium (and that gives the red 
color) was shown to have low but significant estrogenic activity. Besides, FBS that is 
Cycle 23 is 
selected 
 
Cycle 27 is 
selected 
Cycle 19 is 
selected 
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used to supplement the media may also contain various steroids and other hormones 
that might affect the response of cultured cells to RA.  We have asked the question 
whether RA by itself is sufficient for mgNIS upregulation, or other additional ligands 
are essential for, or contribute to, the effect of RA in this regulation. In order to 
clarify this point, we have grown cells in DMEM medium without phenol red. 
Charcoal treatment is a well-known method to remove lipidic substances and ligands,  
such as steroids, from the growth media. Therefore, in addition to using phenol red-
free medium, we have treated the FBS that was added into the media with charcoal. 
We are referring to this supposedly relatively low steroid, or steroid-free media as 
the “minimal media” (MM) in this text (also see Materials and Methods). After 
culturing MCF-7 cells in this medium for 1-2 weeks, these cells are treated with 10-6 
M RA for 24, and 48 hours and we compared mgNIS mRNA levels in MCF-7 cells 
which are grown in DMEM with phenol red supplemented with 10% FBS (normal 
growth medium (NGM)) after a similar hormonal treatment. By performing semi-
quantitative PCR it is found that, hNIS mRNA level is 2,5 times decreased in 
minimal media grown RA treated cells as compared to normal (phenol red and 
untreated 10% FBS containing) media grown RA treated cells (Fig. 3). Besides, there 
were no significant difference in mgNIS mRNA levels between 24h and 48h RA 
treatments (Fig. 3).  
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Fig. 3. Comparison of RA treatment of MCF-7 cells grown in minimal media vs. 
normal media. MCF-7 cells are treated with 10-6 M tRA for 24h and 48h. MCF-7 
cells which are grown in MM (B) gave 2,5 times decrease in hNIS mRNA level 
when compared with cells grown in NGM. There is no significant difference between 
24h, and 48h treatments. A) Lane 1,2,5,6 are MCF-7 cells grown on MM. Lane 
3,4,7,8 are MCF-7 cells grown on NGM. GAPDH is used as control for equalizing 
cDNA amounts.(mass intensity: intensity/pixel) 
 
 
This experiment has clearly shown that in the presence of RA, additional factor(s) 
that are absent in minimal media contribute to mgNIS regulation in MCF-7 cells. 
Identification of this (or these) factor(s) may lead to important clues about the 
molecular mechanisms operating for mgNIS regulation under these conditions. 
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Expected position 
 for amplified NIS
3.4. 17-Est treatment of MCF-7 cells 
Bearing in mind that 17-β-estradiol (17-Est) upregulates mgNIS expression 
when it is administered to overiectomized mice (Tazebay et al. 2000; Cho et al., 
2000), and that the MDA-MB-231 cell line which is ERα(-) does not express mgNIS 
upon RA treatment, we asked the question whether 17-Est can be one of these 
additional factors. Thus, we desired to see whether this ligand can induce mgNIS 
expression in MCF-7 cell lines. Therefore, we treated MCF-7 cells with 10-10 M 17-
Est for the time periods of 0h, 12h, 24h, and 48h. Then, we assessed the mgNIS gene 
activity by RT-PCR. In this experiment the MDA-MB-231 cell lines were used as 
negative control because of their ERα(-) status. As it is seen in Fig. 4, we were not 
able to detect mgNIS mRNA in MCF-7 cells, while PS2 gene which is under control 
of ERs was upregulated in MCF-7 cells as compared to MDA-MB-231.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Effect of an estrogen on mgNIS gene expression in MCF-7 cells. MCF-7, 
and MDA-MB-231 cells are treated with 10-10 M 17-Est in normal growth 
medium(DMEM wh ph. Red. + 10% FBS + 1% P/S) for 0h, 12h, 24h, and 48h. RT-
PCR is made from total RNA by hNIS, hGAPDH, and hPS2 primers. NIS was 
undetectable in all cDNA samples. GAPDH is used as control to check the integrity 
of cDNAs. PS2 is an estrogen responsive gene of unknown function (Jakowlew et al. 
1984), and it is used as a control of ER activity. 
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3.5. Dose dependent estrogen treatment of MCF-7 cells grown in steroid free 
minimal medium. 
We were not able to activate NIS expression by treating MCF-7 cells with 10-
10 M 17-Est for 48 hours (Fig. 4). Then, we treated MCF-7 cells with increasing 17-
Est concentrations. In these experiments we have again used the special minimal 
media composition as described above and in Materials and Methods. It is also 
important to keep the cells in this estrogen-free special media in order to prevent any 
interference of intracellular and media-borne estrogens with the administered doses 
of the same hormone. Accordingly, we have cultured MCF-7 cells for one week in 
this special media prior to treatment with various concentrations of 17-Est from 10-10 
to 10-7 M. In the same experiment, we also wanted to treat separate groups of MCF-7 
cells with same concentrations of 17-Est together with tamoxifen which is an 
antagonist of both ERα and β (Elgort et al., 1996; Zou et al., 1999; and references 
within). These last conditions were added to the experiment thinking that, in case an 
increase is seen in mgNIS expression in response to higher concentrations of 17-Est, 
then a negation of this increase in presence of tamoxifen would give an experimental 
evidence concerning the role of ERs in this upregulation. Accordingly, in a 
preliminary experiment groups, MCF-7 cells are treated for 24h with these ligands at 
following concentrations: 10-10 M 17-Est + 10-8 M tamoxifen; 10-9 M 17-Est + 10-7 M 
tamoxifen; 10-8 M 17-Est + 10-6 M tamoxifen, 10-7 M 17-Est + 10-5 M tamoxifen. 
Unfortunately, last 2 groups of cells were dead in a very short time like half an hour. 
This may be due to the high concentrations of tamoxifen, which might be toxic. As 
seen as a result of an RT-PCR analyses shown in Fig. 5, very surprisingly, the 
combination of 17-Est with tamoxifen resulted in induction of mgNIS while there 
were no induction in 17-Est treated samples. 
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Fig. 5.  Effect of increasing concentrations of estrogen on mgNIS gene 
expression in MCF-7 cells. MCF-7 cells which are grown in MM (see text) are 
treated with 10-10, 10-9, 10-8, 10-7 M 17-Est (indicated as E in the Fig.), and 
combinations of 10-10 M 17-Est plus 10-6  M Tamoxifen (T in the Fig), 10-9 M 17-Est 
plus 10-5 M T for 24 h. C- is non treated, and C+ is RA treated MCF-7 cells. RT-
PCR is made from total RNA by hNIS, and hGAPDH  primers. GAPDH is used as 
control to check the integrity of cDNAs. Combination of 17-Est and tamoxifen 
resulted in an activation of NIS gene in mRNA level. 
 
 
Activation of human RARα gene promoter by ERβ in presence of tamoxifen was 
previously discovered (Zou et al., 1999). Surprisingly enough, they have shown that 
tamoxifen is a ligand that acts as the agonist of ERβ in this promoter (hRARa 
 
promoter) context. Even more surprisingly, again in this promoter context 17-Est acts 
as the antagonist for ERβ (Zou et al., 1999). Our result on NIS gene expression in 
presence of tamoxifen as presented in Fig. 5 fits well to this scheme (see the 
Discussion part). 
 
3.6. Estrogen and RA treatment of MCF-7 cells:    
Estrogen is known to be upregulate the RA receptor (RAR) protein levels in 
human cells in culture (Zou et al., 1999). Then, RAR upregulates the genes that are 
under its control. If such a regulatory cascade applies to mgNIS regulation also, this 
would explain why mgNIS expression is not observed in ERα(-) MDA-MB-231 cells 
upon RA treatment, whereas it is seen in ERα(+) MCF-7 cells under the same 
conditions. Therefore, we could speculate that estrogen might have an indirect effect 
NIS 
GAPDH 
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on mgNIS transcription by upregulating the RAR protein level, leading to indirect 
activation of mgNIS via ERα. To study this possibility, we have grown MCF-7 cells 
in DMEM without phenol red with 3% charcoal treated FBS (MM), or normal 
growth medium (NGM) for 1-2 weeks. Then these cells were treated with either 10-6 
M RA, or 10-6 M RA plus 10-10 M 17-Est for 24 hours. Between two groups of cells 
Fig6, lane 1-3, and lane 2-4 there were no difference in mgNIS mRNA level (which 
were grown in same medium), so between 17-Est and RA vs only RA, no difference 
is observed in mgNIS mRNA accumulation in MCF-7 cells. 
 
 
MM     +      -     +      -     +       - 
NGM     -      +     -      +     -      + 
RA     +      +     +      +     -       - 
17-Est     -      -     +      +     -       - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Treatment of MCF-7 cells that were grown in different media with RA, 
17-Est, and 17-Est+RA.  MCF-7 cells are treated with 10-6 M RA, and 10-6 M +10-10 
M 17-est for 24h. MCF-7 cells which are grown in MM (see text) gave 2,5 times 
decrease (B) in hNIS mRNA level when compared with cells grown in NGM upon 
treatment with either RA, or RA with estrogen. There is no significant difference 
between 17-Est+RA or RA treatments. A) Lane 1,3,5 are grown in MM, Lane 2,4,6 
are grown in NGM.(mass unit : intensity/pixel) 
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Thus we can state that under these experimental conditions, not only 17-Est does not 
induce mgNIS expression in tested mammary cell lines, but also it does not have a 
significant additive up regulatory effect when given together with RA. 
To understand the decrease reason of mgNIS expression in MM grown cells 
compared to NGM grown cells, we designed another experiment. We used the same 
concentration of normal and charcoal treated FBS at this experiment. We grown 
MCF-7 cells in DMEM with phenol red, and DMEM without phenol red with either 
3% FBS, or 3% charcoal treated FBS. These cells were treated with either 10-6 M 
RA, or 10-7 M 17-Est, or 10-6 M RA after treatment with 10-10 M 17-Est for 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7. RA, 17-est,and 17-est plus RA, treatments of MCF-7 cells grown on 
different medium compositions. MCF-7 cells were grown in four different growth 
mediums DMEM w/o phenol red, DMEM with phenol red either with 3% FBS or 3% 
char-coal treated FBS. Lane 1,5,9,13,are grown in DMEM with phenol red plus 3%  
FBS, Lane 2,6,10,14 are grown in DMEM with phenol red plus 3% treated FBS, lane 
3,7,11,15 are grown in DMEM without phenol red plus 3% FBS, lane 4,8,12,16 are 
grown in DMEM without phenol red plus 3% treated FBS. All group of MCF-7 cells 
which are treated with 10-7 M 17-est did not induced NIS transcription. All group of 
cells which were treated with either RA, or estrogen plus RA did not gave a 
difference in NIS mRNA level. pS2, ER responsive gene, levels in each group of 
cells, and in each treatment did not significantly changed. The reason can be that pS2 
mRNA level can be huge in these cells, and semi-quantitative PCR may not 
sufficient enough to detect changes in mRNA levels.  
 
 
If we look at 17-Est treatment again there were no induction of hNIS 
expression in none of the samples(Fig.7 lanes 1,2,3,4). In RA treated cells after 17-
Est treatment (Fig.7. Lanes 13, 14, 15, 16), we tried to analyze 17-Est effect on NIS 
induction via RA, if 17-est is introduced before RA treatment, but we could not 
 GAPDH 
NIS 
pS2
                10-7 M 17-est           Non                     10-6 M RA           10-10 M 17-est(24h prior to RA)  
           + 10-6 M RA 
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detect any induction in none of the samples. In both two sets of  treatments (RA and 
EST+RA) of 4 MCF-7 cell groups, there were no significant change in hNIS  mRNA 
level.  
If we look at RA, and 17-est + RA treatments of cells grown in 4 different 
medium, it was easily seen that there was no difference in mgNIS mRNA expression 
between them. Thus serum concentration was important in mgNIS upregulation upon 
RA induction, and serum concentration increase gives additional effect on mgNIS 
upregulation obtained by RA. (Look Fig 3, and 7) 
 
 
3.7. ERα transfection to MDA-MB-231:   
In parallel to studies on the effect of various media compositions and ligands 
on mgNIS expression in MCF-7 cells in culture, we have asked the question whether 
ERs could contribute to, or necessary for, RA induction of mgNIS. MDA-MB-231 is 
a human breast cancer cell line, which is ERα negative (Fig. 1). This cell line can be 
considered RAR positive albeit the amount of RARα is lower compared to the MCF-
7 line (Fig.8). mgNIS expression in this cell line (MDA-MB-231) is not responsive 
to RA (Kogai et al., 2001; and Fig. 2)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. RARα status of MDA-MB-231 and MCF-7 cell lines. Total protein was 
isolated from MCF-7 and MDA-MB-231 cell lines and a Western blot analysis was 
performed using a polyclonal anti-human RARα Ab. RARα protein is detected in 
both cell lines tested, albeit at different concentrations (indicated with arrowhead).  
 
MDA-MB-231-ERα     MDA-MB-231          MCF-7 
RARα 
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66 kD 
29 kD
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We hypothesized that if ERs have a direct or indirect role in RA regulation of 
mgNIS in MCF-7 cells in culture, then by transfecting the MDA-MB-231 (RA non-
responsive) cell line with ERα we might activate RA responsiveness of mgNIS 
transcription in this line. To conduct this analysis, we stably transfected the MDA-
MB-231 cell line first with the pcDNA3.1c vector plasmid containing the human 
ERα gene (see Materials and Methods). This plasmid was a kind gift of Dr. Ediz 
Demirpençe from The Hacettepe University Faculty of Medicine. ERα was 
subcloned to pcDNA3.1c by Hani Al Otabi. The vector was containing a geniticine 
(G-418) resistance selection marker gene. 20 clones were isolated after 3 weeks of 
antibiotic selection, and these clones were analyzed for ERα expression. First, we 
have screened these clones by a PCR based method for ERα genomic integration 
(see Materials and Methods). Primers used in this analysis are designed in such a 
way that only the integrated ERα cDNA and not the intron containing genomic copy 
is obtained. 7 clones are found to contain the ERα gene integrated in their genome 
(Fig. 9) 
 
 
 
 
 
 
Fig. 9. Integration of ERα gene containing vector plasmids into the genome of 
MDA-MB-231 clones. MDA-MB-231 clones are screened for ERα gene integration 
to their genomes by a PCR based method. Clones with ERα gene integration gave an 
amplification of 226 bp DNA after the PCR. Clones 2, 3, 4, 8, 9, 17, 20 turned out to 
be positive in this analysis. The fragment corresponds to a portion of the ERα cDNA. 
 
Expression of ERα mRNA in these 7 clones that were detected positive for Erα-
pcDNA3.1c integration, are analyzed by RT-PCR analyses. Although the expression 
levels of ERα mRNA varied between different clones, they were all positive for 
transcriptional expression of genome integrated ERα gene (Fig. 10). This is also 
checked by Western blots (see below, Fig. 11). 
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Fig. 10. Expression of the ERα gene in stably transfected MDA-MB-231 clones. 
Clones    2, 3, 4, 8, 9, 17, and 20 gave a significant amplification with primers 
corresponding to a partial sequence of ERα at expected size of 226 bp at the left side. 
– is negative control of PCR. The right site was a PCR that is done with RNA 
templates, that they were in a reaction of cDNA synthesis but reverts transcriptase is 
absent. 
 
A Western blot analysis conducted on samples from these seven clones has shown 
that clone 17 is the only clone that does express the ERα protein (Fig. 11). Therefore 
we have conducted further studies using clone 17. From this point on, in this text, we 
are going to refer to this clone (17) as MDA-III.  
 
 
 
 
 
 
 
 
 
 
Fig. 11. Screening of MDA-MB-231 stable clones for ERα protein expression. 
Total protein was isolated from MCF-7, MDA-III and MDA-MB-231 cell lines and a 
Western blot analysis was performed using monoclonal anti-human ERα Ab. ERα 
protein is detected in MCF-7 and MDA-III cell lines (indicated with arrowhead), 
whereas it is not detected in MDA-MB-231 cell lines.  
 
 
Subsequently, we have carried out a Southern blot analysis on MDA-III, simply to 
confirm the integration of ERα gene in the genome of this clone, and to identify the 
region in genome where the gene is integrated. This study also gave us an idea about 
the copy number of the ERα plasmid in MDA-III clone. Looking at this result we 
MDA-III MDA MCF-7
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25 kD
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can state that only one copy of the externally introduced gene was actually integrated 
into the genome (Fig. 12). For Southern analysis, the BglII restriction enzyme is 
used. This enzyme cuts only once in the ERα gene, and it does not have any site in 
the vector plasmid pcDNA3.1c (see Material and Methods).  Thus in a Southern 
analysis after cutting the genomic DNA by BglII we could observe the integration of 
the transfected plasmid (Fig. 12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. Integration of externally introduced ERα gene into the genome of the 
clone MDA-III. Lane1, and lane2 are BglII cut genomic DNA of MDA-MB-231-III, 
and MDA-MB-231 respectively. Lane 3, and lane 4 are uncut genomic DNA of 
MDA-MB-231-III, and MDA-MB-231 respectively. Integrated ERα gene is detected 
around 2.2 kb (see Materials and Methods). 
 
After observing the ERα expression in MDA-III cells at the protein level 
(Fig. 11), we aimed to check the ERα activity in this clone. For this purpose, MDA-
III cells were transiently transfected with a vector plasmid containing the reporter 
gene, luciferase, under control of an estradiol responsive element (ERE). If the ERα 
protein detected in the clone III is biologically active, then it would interact with the 
ERE region in this plasmid and activate the reporter luciferase expression in response 
to 17-est. As seen in the graph in Fig. 13, MDA-III transfectants of ERE-reporter 
plasmid gave a 2 fold activation when compared to cells transfected with pGL3, a 
plasmid expressing the luciferase gene constitutively, thus we used as a luciferase 
M 1 2 3 4
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detection control. While it gives nearly same luciferase count when as pGL3 basic 
plasmid when they did not treated with 17-est, fig. 13. These results show us that 
ERα protein in MDA-MB-231-III cells are most probably functional. This 
experiment is performed only once, so it should be repeated to be sure that MDA-
MB-231-III cells contain functional ERα protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13.  Luciferase activity assay of ERE response element transfected to MDA- 
III stable clone. MDA-III cells are transfected with various reporter plasmids 
containing luciferase gene under control of different promoters. pGL3basic contains 
only the ORF of the luciferase gene. pGL3control  contains the luciferase under 
control of a constitutive SV40 promoter, thus this is the positive control in this 
experiment. In ERE the reporter gene is under control of an estrogen responsive 
element cloned with a basal β-globulin promoter. ERE(est); ERE transfected MDA-
III cells are treated with 10-10 M 17-Est for 24 hours and luciferase activity is 
compared with untreated cells, ERE(non).Luciferase activities was normalized with 
GFP transfection efficiencies of each transfection. 
 
3.8. Absence of mgNIS upregulation in MDA-III cells in response to RA or 17-
Est. 
  MDA-III cells and the MCF-7 cell line were treated with 10-6 M RA, or 10-6 
M RA plus 10-10 M 17-est for 24 hours. RT-PCR analysis is made with treated 
samples, and as seen in Fig. 14, there were neither NIS expression nor PS2 
expression in MDA-III, while GAPDH was expressed in all samples. This result may 
indicates that the presence of ERα in  
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Fig. 14. MDA-III treatment with RA, and RA+Est. MDA-III is treated with either 
10-6 M RA or  10-10M 17-Est + 10-6 M RA. In presence of neither of two ligands 
mgNIS is expressed in MDA-III. GAPDH is used as control to check the integrity of 
cDNAs. PS2 is an estrogen responsive gene of unknown function (Jakowlew et al. 
1984), and it is used as a control of ER activity.C+ is MCF-7 treated with RA. C- is 
non treated MDA-III 
 
 
 
MDA-III cell line may not sufficient for mgNIS expression in presence of RA or 17-
Est. 
 
3.9. Sub-cloning of  long form rat prolactin receptor  
 Besides our analysis on the role of ERα on mgNIS expression, we aimed to 
study a possible role of prolactin and rat prolactin receptor (rPRLR) in mgNIS 
regulation in mammary cells in culture. To this end, we have sub-cloned the long 
form of rat PRLR into pcDNA3.1 plasmid in frame with his, and myc tag (see 
below). cDNA was amplified from rat ovary, and RT-PCR was performed by using 
rPRLR primers (see Materials and Methods) using these cDNA as template (Fig. 15). 
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Fig. 15.  Amplification of full length rPRLR coding sequence. Long form of prlR 
was amplified at expected size of 1.99 kb. 
 
After cloning the amplified product into pcDNA3.1c mammalian expression vector, 
the recombinant plasmid was checked by restriction enzyme digestion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. Restriction enzyme digest analysis of recombinant vector.  
Lane1,2,3 are prlR-pcDNA3.1c digests, lane 4,5,6 are pcDNA3.1c digests. 
Expected fragments are seen in figure. 
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This expression plasmid  including rPRLR gene, was transfected to Hek-293 cells, 
and transfected cells were analysed by western blot for PRLR presence with myc 
antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. Western blot analysis of transiently transfected Hek-293 cells with 
pcDNA3.1c-rPRLR. Lane 1 is Hek-293 transfected with PRLR-pcDNA3.1c, lane2 
is Hek-293 cells transfected with pcDNA3.1c, lane3 is Hek-293 cells. PRLR protein 
is detected with α-myc antibody in PRLR-pcDNA3.1c transfected cells only. 
 
In previous studies in overiectomized mice, PRL had an effect on mgNIS 
regulation, when it was administered with estrogen, and oxytocin (Tazebay et al. 
2000). Additionally Rillemma et al. showed that prolactin increased mgNIS in 
mRNA, and protein level in 30D histocultured mid-pregnant mammary gland 
explants. Prolactin stimulatory effect on NIS expression was also established in 
Nancy Carrasco’s laboratory, that when PRLR was introduced into CHO-K1 cells, 
and treated with prolactin and insulin, these cells expressed NIS protein. In parallel 
to these studies and results, we decided to construct stable CHO-K1 constructs with 
PRLR to study prolactin effects on exogenous rNIS promoter deletions constructed 
by Hani al Otabi. In order to achieve this goal we first cloned long form of rat 
prolactin receptor into pcDNA3.1c with his and myc tag (fig. 16, and fig. 17), and 
checked its expression in Hek-293 cells, fig. 17. Then we stably transfected rPRLR 
into CHO-K1 cells, and isolated 90 colonies. Screening procedure for rPRLR 
expression is not done yet.  
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                    4.Discussion 
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Identification of NIS protein in the lactating mammary gland was a start point 
to many interesting studies. One aspect of the mgNIS that is completely unknown is 
the molecular determinants of the transcriptional regulation of this gene. Several 
hormones that regulate NIS in mammary gland (mgNIS) were identified in previous 
studies (Cho et al., 2000; Tazebay et al., 2000; Rillema et al., 2000). However, 
transcription factors that regulate NIS expression in the mammary gland, and cis-
acting enhancer elements located in NIS upstream regulatory region that are essential 
for regulation in mammary gland are to be studied.  
 Some of the previously published studies indicated that estrogens may play a 
role in mgNIS regulation (Tazebay et al., 2000; Cho et al., 2000; Kogai et al., 2001). 
Yet, clear evidences showing the role of estrogen receptors in regulation of mgNIS 
were missing. Similarly, prolactin was shown to be a hormone that upregulates 
mgNIS protein expression and iodide transport activity, in various experimental 
settings both in vivo and in vitro (Tazebay et al., 2000; Rillema et al., 2000). In this 
thesis, we have inquired 1) the contribution of estrogens to mgNIS regulation in 
human mammary gland cells in culture; 2) a possible role of human estrogen 
receptors α and β in mgNIS regulation in human mammary gland cell lines in vitro.  
  We have used two human breast carcinoma cell lines: the MCF-7, and the 
MDA-MB-231. MCF-7 cells are both ERα(+) and ERβ(+). Whereas, MDA-MB-231 
cells are both ERα(-) and ERβ(-). MDA-MB-231 is commonly used in studies 
related with estrogen action in mammary cells (Kogai et al., 1999; Gross and Yee, 
2002). We were, in a way, obliged to work with the MCF-7 cell line because this is 
the unique breast cell line in which mgNIS expression was detected. Importantly, RA 
was shown to be absolutely necessary for this induction (Kogai et al., 2001).  
  In experiments using minimal media we have inquired whether ligands or 
substances other than RA may affect mgNIS regulation in in vitro conditions (Figs. 3 
and 7). In these experiments we have kept the RA concentration in media constant, 
but we changed the FBS concentration and we removed phenol red (see Materials 
and Methods). We have seen no difference in mgNIS expression between the 
medium containing phenol red vs the phenol red-free medium (Fig. 7). Also, we have 
seen no difference under conditions when treated vs non-treated serum are used in 
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media (Fig. 7). However, decreasing the FBS concentration from 10% to 3% affected 
mgNIS expression 2,5 fold in presence of constant amounts of RA (Figs. 3 and 7). 
This means that in addition to RA, serum-borne factors directly or indirectly 
contribute to mgNIS regulation without affecting GAPDH levels in MCF-7 cells.  
  Because the effect of 17-Est on mgNIS regulation was previously shown 
(Tazebay et al., 2000; Cho et al., 2000) in vivo, we inquired whether the unidentified 
serum component contributing to RA regulation may be estrogens or not. We first 
treated both MCF-7 cells, and RA non-responsive MDA-MB-231 cells, with 17-Est 
in physiological conditions (10-10 M). We did the treatment in different time periods 
between 0h, and 48h. We could not detect mgNIS mRNA by RT-PCR analyses in 
any time period in none of the cells. Estrogen in physiological conditions was not 
able to activate endogenous mgNIS promoter in these cell lines, as it was in 
overiectomized mice mammary glands in vivo (Tazebay et al., 2000). Either the 
transcription factor repertoire of MCF-7, and MDA-MB-231 cell lines are different 
from overiectomized mice mammary gland cells, or there are ligands that are 
essential for mgNIS gene transcription in vivo, and that they are absent in media we 
grow our cells.  
Under in vivo conditions, concentration of estrogen may increase up to    
10-8 M according to the physiological condition of the female body (Yoshinaga et al., 
1969) Thus, we decided to gradually increase the concentration of 17-Est in cell 
culture media, and make an estradiol dose dependent analysis of mgNIS expression 
in MCF-7 cell lines. We used different concentrations of estrogen from 10-10 to 10-7. 
In addition, in separate samples we treated cells with the same amounts of estrogen 
together with tamoxifen (from 10-6 to 10-5). By RT-PCR we could not detect a 
significant amount of mgNIS gene expression when cells are treated with 10-7 M of 
17-Est. But very interestingly, we detected a significant weak induction of mgNIS in 
samples treated with estrogen together with tamoxifen. This fits very well to the 
observations of Zou et al. (1999) on the activation of human RARα gene promoter 
by ERβ in presence of tamoxifen as its ligand. These experiments have shown that in 
HepG2 cells transiently transfected with ERβ gene, RARα promoter gets activated in 
response to tamoxifen. For this activation, ERβ does not bind to promoter DNA 
sequences of RARα gene, but cis-acting SP1 binding sites are necessary for the 
activation. Thus the effect of ERβ in this upregulation seems to be indirect. 
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Surprisingly, estrogen has an antagonistic effect on this activation of ERβ (and then 
RARα gene) by tamoxifen (Zou et al., 1999). This may also explain our results 
presented in Fig. 5. Besides, it may give hints about a possible link between ER 
action and RA effect in mgNIS regulation. In our case, by RT-PCR we have seen an 
amplification product corresponding to mgNIS after treatment of MCF-7 cells with 
10-6 M tamoxifen together with 10-10 M 17-Est. We could propose two possible 
mechanisms based on Zou et al (1999)’s data in order to explain this observation: 1) 
ERβ may upregulate mgNIS gene directly or indirectly in response to a tamoxifen 
dependent activation; 2) as shown by these authors, ERβ may activate RARα 
expression in presence of tamoxifen, which in turn might activate mgNIS promoter 
by binding to RARα responsive elements (Schmutzler et al., 2002).  
RA induction of mgNIS was seen by Kogai et al. (2001) in human MCF-7 
cells, which is a cell line that is both ERα and ERβ (+). This induction is absent in 
the ERs (-) MDA-MB-231 cells. Thus, one of the hypotheses was on the role of ERs 
in RA regulation of mgNIS in human mammary cells in culture. In order to test this 
hypothesis, we decided to introduce ERα gene in MDA-MB-231 cells both by 
transient and stable transfections. Plasmid DNA transfections to MDA-MB-231 cells 
were quite cumbersome, with typical transfection efficiencies at about 5%. This has 
obstructed our experiments with transiently transfected cells, and thus we could not 
get significant data from these experiments. However, stable transfection 
experiments worked better and we obtained a transfected colony expressing human 
ERα protein. We named this clone as MDA-III (Fig. 11). In order to assess the 
activity of the externally introduced ERα, we have performed RT-PCR analysis to 
visualize the activation of an estrogen responsive endogenous gene, PS2. However, 
we could not see any significant PS2 or mgNIS upregulation upon 17-Est or RA 
treatment of MDA-III cells. One possible explanation is that the concentration of 
ERα in MDA-III cells is below the necessary threshold for the activation of PS2 by 
17-Est. This might be due to lower expression levels of the introduced ERα gene in 
MDA-III cells as compared to its endogenous expression in MCF-7. In a preliminary 
experiment, we have transfected MDA-III with various plasmids in order to check 
the activity of the externally introduced ERα (Fig. 13). In cells transfected with 
plasmid ERE containing the luciferase reporter gene under control of an estrogen 
responsive promoter, we have detected significantly increased luciferase activity in 
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cells treated with 17-Est as compared to non-treated cells (Fig. 13). Although the 
experiment is to be repeated, it shows that the MDA-III cells contain 17-Est 
responsive ERα. Yet, the presence of this activator in MDA-III cells is not sufficient 
for mgNIS activation in response to RA or 17-Est treatment of cells.  
 Our future perspective is to put more emphasis on ERβ’s role in mgNIS 
regulation in MCF-7 cells. It was known that ERβ activates human RARα gene 
promoter in presence of tamoxifen as the agonist (Zou et al., 1999). A similar 
mechanism may apply to mgNIS regulation in MCF-7 cells (Fig. 5), and ERβ may 
indirectly control the transcription of this gene. If this hypothesis turns out to be true, 
and mgNIS is upregulated by tamoxifen, then this result may have important medical 
applications: mgNIS was shown to be upregulated in ER(+) breast tumors in women 
(Tazebay et al., 2000). Thus, if our hypothesis is correct, then tamoxifen treatment of 
these tumors may lead to an even higher upregulation of mgNIS. Bearing in mind 
that radioactive iodide is used in thyroid cancer diagnosis and treatment (Daniels and 
Haber, 2000), this upregulation of mgNIS in response to tamoxifen may have 
interesting applications in fight against breast cancer. 
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